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PART-1
SYNTHESIS AND CHARACTERIZATION
The chemistry of the heterocyclic compounds is as logical as that of aliphatic or
aromatic compounds. The variety of heterocyclic compounds is enormous, their chemistry
is complex and synthesizing them requires great skill.
This class of compounds have great applicability as drugs due to their specific
chemical reactivity. They resemble essential metabolism and they fit biological receptors
and block their normal working. Many natural products contain heterocyclic compounds
such as alkaloids and glycosides.
Taking in view of the applicability of heterocyclic compounds, the present work
was undertaken to synthesize some new heterocycles bearing triazole and pyrazole nucleus.
CHAPTER-1 - STUDIES ON TRIAZOLES DERIVATIVES
Triazoles are heterocyclic organic compounds having a five-member ring molecular
structure containing three nitrogen atoms. Triazoles are of two types: 1, 2, 4-triazole and
1, 2, 3-triazole. The chemistry of 1,2,3-triazoles and 1,2,4-triazoles were well documented.
The chemistry of triazole derivatives have been of interest due to its useful application in
medicine, agriculture and industry. Further, some of these triazoles are known to be used
as analytical reagents, dyes and photographic chemicals and in the preparation of
polymers.
Prompted by the biological activities of 1,2,4-triazole and as a part of our general
search concerning chemotherapeutically important azoles heterocycles, in present work,
an attempt has been made to synthesize some 4-amino-3-mercapto 1,2,4-triazole
derivatives.
SECTION-I -  STUDIES ON SCHIFF BASES
The azomethine derivatives of 1,2,4-triazole have been found to be potent drug
pharmaceutical industries and possess a wide spectrum of biological activity.
Azomethines can be formed by the reaction of a primary amine with aldehyde with
the simultaneous removal of water. The loss of water, give an imine, corresponds to the
“Crotonaldehyde stage” of the aldol condensation. Several methods have been reported
for the preparation of azomethines. These observations led us to synthesise Schiff bases
bearing 1,2,4-triazole moiety to enhance the overall activities of resulting moiety.
SECTION-II-  STUDIES ON 4-ARYL TRIAZOLES
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1,2,4-triazole and their derivatives constitute an important class of organic
compounds. Amongst the five membered nitrogen containing heterocycles, the position
of nitrogen atom at 1,2 and 4 activates the ring.
The synthesis of these heterocycles has received considerable attention in recent
years. Several methods have been reported in the literatures for the preparation of 4-aryl
triazoles.
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SECTION-III -  STUDIES ON 1,3,4-THIADIAZOLO TRIAZOLES
Thiadiazoles are the compounds containing three carbon atoms, one sulphur atom,
and one nitrogen atom in five member ring. It is parent material for numerous of chemical
compounds including sulfur drugs, biocides, fungicides, dyes, chemical reaction
accelerators. Thiadiazoles and its derivatives are important in the industry of dyes,
photographic chemicals, sulfa drugs, preservative and rubber.
Such compounds find application for making biological activitive agents.
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Compounds of Type-2 can be synthesized by the condentation of different aro-
matic aldehydes with 1,2,4-triaole.
                                                               Type-2
      By the reaction of aromatic carboxylic acids with 1,2,4-triazole, compounds of
Type-1 can be synthesized.
                                                              Type-I
T
CHAPTER-2 - STUDIES ON PYRAZOLES
One of the most useful class in heterocyclic compounds is Pyrazole. The pyrazole
ring consists of a doubly unsaturated five membered ring containing two adjacent nitrogen
atoms.
The research on the chemistry of pyrazoles has been a focus of attention for
chemists for a long time, due to their wide spread diversified biological activities like
antitubercular, antimicrobial, hypnotics, anti-inflammatory, antitumor, plant growth regulators
and are also used as herbicidal and fungicidal.
Considering the increasing importance of pyrazole nucleus, the synthesis of some
new chalcones, pyrazolines, cyanopyridines, thiazolidinones  has been undertaken.
N N
CHO
NO2
SECTION-I- STUDIES ON CHALCONES
The chemistry of chalcones has generated intensive scientific studies throughout
the world. Specially interest has been focused on the synthesis and biodynamic activities
of chalcones. In chalcones two aromatic rings are linked by an aliphatic three carbon
chain. Presence of α,β-unsaturated carbonyl group gives good biological activity.
N
N
O
NO2
R
R = Aryl
SECTION-II- STUDIES ON PYRAZOLYLPYRAZOLINES
Pyrazolines are well known for their varied applications in the field of medicine.
Amongst nitrogen containing five membered heterocycles, pyrazolines have proved to be
the most useful framework. These pyrazoline derivatives  have been prepared by the
reaction of chalcones with hydrazine hydrate.
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SECTION-III-  STUDIES ON CYANOPYRIDINES
Pyridine is belonging to an important class of heterocyclic compounds with
applications in the field of medicine, agriculture and industrial chemistry. Some pyridine
derivatives are active in the metabolism of body and also used as a denaturant for
antifreeze mixtures, as a dyeing assitant in textiles and fungicides.
R = Aryl
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CHAPTER-3- COMPARISION OF DIFFERENT SYNTHESIS METHODS
In the last few years Microwave-induced Organic Reaction Enhancement (MORE)
chemistry has gained popularity as a non-conventional technique for rapid organic synthesis.
Many researchers have reported the synthetic utility of MORE chemistry in routine organic
synthesis. Compared to traditional processing of organic synthesis, microwave-enhanced
chemistry saves significant time and very often improves conversions, clean product
formation.
Ultrasound waves are known for their wide applications in various fields like life
sciences, medical, cleaning, sonar, electronics, agriculture, oceanography, material science
etc(. Further, these waves prove to be important in synthetic organic chemistry by lowering
the reaction temperature and reaction time. By using these waves, yield can be increased
and one can avoid the use of phase transfer catalysts in chemical reactions.
This prompted us to synthesize various substituted pyrazoline derivatives using
the Microwave-assisted (MW) method, Ultrasound irradiation (US) and Conventional
thermal (Con.) method.
SECTION-IV-  STUDIES ON THIAZOLIDINONES
It has been reported that compounds bearing thiazolidinones nucleus show wide
range of biological activities such as antitumor, antileprosy, antitubercular and  anti-
bacterial etc. By considering these valid observations, we have synthesized some
new 5-arylidine-4-thiazolidinones shown as under.
S
NN
R R
O
N
N NO2
R = Aryl
N N
NO2
N
N
R
N
N
NO2
N
N
RO
CH3
R = Aryl
R = Aryl
PART-2
PHYSICO CHEMICAL PROPERTIES
CHAPTER-1-  ACOUSTICAL PROPERTIES
In  this chapter, sound velocity studies of some triazole derivatives in
dimethylformamide (DMF) and tetrahydrofuran(THF) solution were done at 308.15 K with a
view to understand the molecular interactions in these solutions. From these experimental
data, various acoustical parameters such as isentropic compressibility, Rao’s molar sound
function, specific acoustical impedence, internal pressure, Vander Waals constant, free
volume etc. were evaluated and results are discussed.
CHAPTER-3- CONDUCTANCE
The solutions of different concentrations were prepared for each Schiff base in
DMF and DMSO and the conductance of each solution was measured and equivalent
conductance at infinite dilution for different schiff bases was evaluated.
CHAPTER-4-  THERMAL PROPERTIES
 This chapter describes the thermal properties of Schiff bases. The Differential
Scanning Calorimetry (DSC), Differential Thermal Analysis (DTA) and Thermo Gravimetric
Analysis (TGA) measurements were made. Thermal method of analysis like TGA is
employed in the study of the thermal behaviour of compounds and more particularly about
their thermal stability.
CHAPTER-5-  HEAT OF SOLUTIONS
The molar heat of solution and melting temperature of a substance can be deter
mined  from the solubility measurement at different temperatures . In the present work,
heat of solutions for all the Schiff bases were determined at different temperatures
(35-55°C) in THF and 1,4-dioxane.
In this chapter, the density and refractive index of all triazole Schiff bases have
determined in Dimethylformamide (DMF) and Tetrahydrofuran (THF) solutions at  308.15
K. Refractive index is a property of the material and is extremely useful in chemical analysis.
CHAPTER-2-  DENSITY AND REFEACTIVE INDEX
            Biological Activity Spectrum of a compound represents the pharmacological effects,
physiological and biochemical mechanisms of action, specific toxicity which can be
revealed in compound’s interaction with biological system. Further, it describes the intrinsic
properties of the compound which depends on its structure. Most of known biologically
active substances have many different biological activities such as antibacterial, anti-
inflammatory,antifungal,anti-HIV,antipyretic,antitumoretc.
           A literature survey shows that a number of triazole derivatives have good antibac
terial and antifungal activities.  Considering these properties of triazole derivatives, in
the present chapter, antibacterial and anti-fungal activities of some triazole deriva-
tives were studied.
BIOLOGICAL ACTIVITIES
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PART-3
GENERAL INTRODUCTION
The chemistry of the heterocyclic compounds is as logical as that
of aliphatic or aromatic compounds. The variety of heterocyclic compounds
is enormous, their chemistry is complex and synthesizing them requires
great skill.
A heterocyclic compound is one which possesses acyclic structure
with at least two different kinds of atoms in the ring. Among large number of
heterocycles found in nature, nitrogen heterocycles are the most abundant
than those containing oxygen or sulfur. The number of atoms in the
heterocyclic ring can range from three to many i.e. ethylene oxide to crown
ethers. Heterocyclic compounds can contain more than one ring system
either heterocyclic or homocyclic.
Heterocyclic systems are encountered in many groups of organic
compounds possessing great applicability in industry as well as in our life
in various ways. Most of the sugars and their derivatives contain hetero
atoms. Many members of the vitamin B group possess heterocyclic ring
containing nitrogen.
This class of compounds have great applicability as drugs due to their
specific chemical reactivity. They resemble essential metabolism and they fit
biological receptors and block their normal working. Many natural products
contain heterocyclic compounds such as alkaloids and glycosides. Many
antibiotics including penicillin, cephalosporin, norfloxacin, streptomycin etc. also
contain heterocyclic ring.
Taking in view of the applicability of heterocyclic compounds, the
present work was undertaken to synthesize some new heterocycles bearing
triazole and pyrazole nucleus.
1
INTRODUCTION
Triazoles are heterocyclic organic compounds having a five-member ring
molecular structure containing three nitrogen atoms. Triazoles are of two types: 1, 2, 4-
triazole and 1, 2, 3-triazole. The chemistry of 1,2,3-triazoles and 1,2,4-triazoles were
well documented(1-9). The chemistry of triazole derivatives have been of interest due to
its useful application in medicine(10), agriculture(11) and industry(12). Further, some of
these triazoles are known to be used as analytical reagents(13), dyes and photographic
chemicals(14) and in the preparation of polymers(15).
The first 1, 2, 4-triazole derivative was synthesized by Bladin in 1885. Synthesis
of various triazole derivatives have been reported(16-22). Alkinson and Polya(23)
synthesized 1,3-diphenyl 1,2,4,triazole. From diaroylhydrazines, Klingsberg(24) prepared
triaryl-s-triazoles. Kurzer and Canelle(25)  synthesized some 4-substitutetd 3-amino-5-
mercapto-1,2,4-triazoles. Beresneva et al.(26)  reported synthesis of 3-(1,2,4-trazole-4-
yl)-5-amino 1,2,4-triazole. Preparation and characterization of four isomeric oxodihydro
s-triazolo pyrimidines was studied by Reimlinger and Peiren(27). Synthesis of various
new triazoles have also been reported by several workers.(28-30) Preparation and reactivity
of some mesoionic 1,2,4-triazolo-[4,3-b]-1,2,4-triazole derivatives have been
documented by  Molina et al(31). Szilagyi et al(32)  reported the preparation of new 1,5-
diaryl-3-alkylthio-1H-1,2,4-triazoles and corresponding sulfoxides and sulfones. Reid
and Heindal synthesized triazoles by the reaction of aryl acid hydrazide with CS2/KOH
and Hydrazine hydrate (33). Yasin and co-workers synthesized new triazoles via
conversion of 1-[á-aracyl-β-(2-thienyl)] acrocyl semicarbazides into 1, 2, 4-triazoles.(34)
Kee-Jung Lee et al. prepared 1,2,4-triazoles from the elctrocyclic reaction of conjugated
heterocumelenes.(35)
Literature survey reveals that 1,2,4-triazole nucleus is associated with diverse
pharmacological activities such as anti-inflammatory (36,37), diuretic(38), antiviral(39,40),
antihypertensive(41,42), anthalmentic(43), bactericidal (44,45), anticonvulsant(46-48),
herbicidal(49), insecticidal and acaricidal (50), fungicidal (51,52), antimicrobial (53,54),
anticancer and anti-HIV(55,56), plant growth regulator(57), antileishmanial(58), antitumor(59),
antidepressant and anxiolytic(60,61), anti tuberculosis(62), mycobacterial activity(63,64), A2A
2
3receptor antagonists(65), corrosion inhibitor(66-68), analgesic(69) and antifungal activity (70,71).
Atsuo et.al. have reported  triazoles  as antiheumatic agents(72). Mohammad has also
reported anti-inflammatory activity of 1, 2, 4-triazole derivatives(73). Jag Mohan et. al
have synthesized thiazolo triazoles and studied their antimicrobial activity(74). Slawanski
have prepared some triazoles and studied their potent cardiovascular agent(75). 1, 2,
4-triazoles are also known to inhibit Erisyphegraminis on barley (76).  Carla have
investigated antigestative immuno suppressant and antitumor activity of some
triazoles(77). Uesaka et al. also documented triazoles as adrenergic ∝2C receptor
antagonists(78).
Various drugs have already been synthesized of the medicinal uses which
contains the 1, 2, 4-triazole nucleus. Some of the drugs are: Fluconazole (antifungal),
Rifavirin (antiviral, antiinfections), Diniconazole (agriculture- fungicide), Itraconazole
(antifungal), Bitertanol (fungicide), Triazophose (pesticide), Letrozole (estrogen
inhibitor- antineoplastic), Diclobutrazole (plant growth regulator) and   Rilmazafone
(sedative-hypnotic).
Prompted by the biological activities of 1,2,4-triazole and as a part of our general
search concerning chemotherapeutically important azoles heterocycles, in present
work, an attempt has been made to synthesize some 4-amino-3-mercapto 1,2,4-triazole
derivatives.
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8INTRODUCTION
Azomethines are generally known as Schiff bases to honour Schiff, who
synthesized such compounds(1). These are the compounds containing characteristic –
C=N- group. Lots of works have been done on this class compounds due to its multi
applicability. They are well known intermediate for the preparation of azetidinones,
thiazolidinones, aryl acetamides and many other derivatives. The reaction between
amine and formaldehyde followed by further reaction with compounds having active
hydrogen gives mannich bases.
Azomethines can be formed by the reaction of a primary amine with aldehyde
with the simultaneous removal of water. The loss of water, give an imine, corresponds
to the “Crotonaldehyde stage” of the aldol condensation. Several methods have been
reported for the preparation of azomethines.  Sampat and Mehta gave the detail study
report on heterocyclic Schiff bases legends derived from pyrazole 2-caboxy aldehyde
and pyridine-2-carboxy aldehyde with o-toludine, p-toludine and aniline. Chang and
Pan reported some Schiff bases derived from amino phenols and aromatic
aldehydes(2). More et al.(3) have marked the biological activity of Schiff bases
synthesized from aminothiazoles. Selvam et al. have prepared sulfonamide and its
derivatives as anti-HIV agents(4).
The azomethine derivatives of 1,2,4-triazole have been found to be potent drug
pharmaceutical industries and possess a wide spectrum of biological activity(5-8). Wei
et al.(9) have synthesized new type of Schiff bases containing triazole ring which are
observed to be potential fungicides. Yadawe and Patil have reported some azomethines
which were screened for their antibacterial and antifungal activities(10)  Khalafallah and
Hasan have also suggested some styryl Schiff’s bases as potential antibacterial and
antifungal agents(11).  Holla et al. have documented azomethine bearing triazole moiety
which possess good antibacterial activity(12). Owing to their characteristic properties
like, manifestations of novel structures, thermal stabilities, abnormal magnetic
properties, relevant biological properties, high synthesis flexibility, varied coordinating
ability and medicinal utility, a wide range of these compounds have been synthesized(13-
19) and extensively studied(20-30).
These observations led us to synthesise Schiff bases bearing 1,2,4-triazole
moiety to enhance the overall activities of resulting moiety.
9The following Schiff bases of triazoles have been synthesized for physico
chemical properties.
1: 4-({[3-Mercapto-5-(4-methoxyphenyl)-4H-1, 2, 4-triazol-4-yl] imino} methyl
(HAS-1)
2: 4- [ {4-Methoxybenzy l idene}  amino] -5- (4-methoxypheny l ) -4H-1,  2 ,  4-
triazole-3-thiol (HAS-2)
3: 4-[(4-Fluorobenzylidene) amino]-5-(4-methoxyphenyl)-4H-1,2,4-triazole-
3-thiol (HAS-3)
4: 5-( { [3 -Mercapto-5- (4-methoxypheny l ) -4H -1 ,  2 ,  4 - t r iazo l -4-y l ]  im ino}
methyl)-2-methoxyphenol (HAS-4)
5: 4-[(4-Chlorobenzylidene) amino]-5-(4-methoxyphenyl)-4H-1, 2, 4-triazol
(HAS-5)
6: 4-{[4 -(Dimethylamino) benzylidene] amino}-5-(4-methoxyphenyl)-4H-1, 2,
4-triazole-3-thiol (HAS-6)
7: 5-(4-methoxyphenyl)-4-[(3-nitrobenzylidene) amino]-4H-1, 2, 4-triazole-
3-thiol (HAS-7)
8: 4-[(2-Chlorobenzylidene) amino]-5-(4-methoxyphenyl)-4H-1, 2, 4-triazole-
3-thiol (HAS-8)
9: 2-({ [3-Mercapto-5-(4-methoxyphenyl)-4H -1,2,4- t r iazoly l ] imino}methyl)
phenol (HAS-9)
10: 5-(4-Methoxyphenyl)-4-{[(1E)-phenylmethylene] amino}-4H-1, 2, 4 triazole-
3-thiol (HAS-10)
EXPERIMENTAL
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Synthesis of 4-amino-5-(4-methoxyphenyl)-4H-1, 2, 4- triazole-3-thiol (HAS-E)
All the reactions were carried out using following literature methods.
(1) Synthesis of 4-methoxy benzoate (HAS-B)(31)
4-Methoxy benzoic acid (0.01M) in 20 ml of methanol and 0.5 ml conc.
sulfuric acid was refluxed for 12 hrs. and poured into ice. The product was
isolated and treated with saturated sodium bicarbonate solution. Yield 92%,
M.P. 219 oC
(2) Synthesis of 4-methoxy benzoic acid hydrazide (HAS-C)(31)
A mixture of 4-methoxy benzoate (0.01 M) and hydrazine hydrate (0.5g,
0.01 M) was heated for 9 hrs. and poured into ice. The product was isolated
and crystallized from ethanol. Yield  71%, M.P. 156 oC
(3)  Synthesis of potassium 4-methoxy benzoic acid hydrazide
dithiocarbamate(HAS-D)(32)
A mixture of 4-methoxy benzoic acid hydrazide(0.01 M), KOH (0.84 g,
0.015 M) and 1.5 ml CS2 in absolute alcohol was stirred for 21 hrs. and  product
isolated from diethyl ether. Yield  85%, M.P. 196 oC
(4) Synthesis of 4-amino-5-(4-methoxyphenyl)-4H-1, 2, 4- triazole-3-thiol
(HAS-E)(32)
Potassium salt (0.01 M) was taken in hydrazine hydrate and heated up
to the evolution of H2S gas caused nearly 5 hrs. in oil bath. The reaction mixture
was poured onto crushed ice and treated with gla. acetic acid. The product
was filtered and purified by KOH treatment and crytallised from ethanol. Yield
65%, M.P. 215 oC
(5)  Synthesis of Schiff bases (HAS-1 to 10)(33)
A mixture of HAS-E (0.01M, 2.22gm) and different aromatic aldehydes
was taken in ethanol and 2-3 drops of gla. acetic acid was added and the
reaction mixture was refluxed for 10 hours. The product was isolated and
crytallised by absolute alcohole.
11
O
OH
O
CH3
Me-OH
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SPECTRAL STUDIES OF SCHIFF BASES
INFRA RED SPECTRA
           An invaluable tool in organic structure determination and verification involves
the class of electromagnetic (EM) radiation with frequencies between 4000 and 400
cm-1 (wave numbers). The category of EM radiation is termed infrared (IR) radiation,
and its application to organic chemistry known as IR spectroscopy. Radiation in this
region can be utilized in organic structure determination by making use of the fact that
it is absorbed by interatomic bonds in organic compounds. Chemical bonds in different
environments will absorb varying intensities and at varying frequencies. Thus IR
spectroscopy involves collecting absorption information and analyzing it in the form of
a spectrum.
         The region of the infrared spectrum which is of greatest interest to organic
chemists is the wavelength range 2.5 to 15 micrometers (µ). In practice, units
proportional to frequency, (wave number in units of cm-1) rather than wavelength, are
commonly used and the region 2.5 to 15 µ corresponds to approximately 4000 to 600
cm-1. Absorption of radiation in this region by a typical organic molecule results in the
excitation of vibrational, rotational and bending modes, while the molecule itself remains
in its electronic ground state.
 For the purpose of routine organic structure determination, using a battery of
spectroscopic methods, the most important absorptions in the infrared region are the
simple stretching vibrations. For simple systems, these can be approximated by
considering the atoms as point masses, linked by a ‘spring’ having a force constant k
and following Hooke’s Law.
Instrument: SHIMADZU-FT-IR 8400 Spectrophotometer
Frequency range: 4000-400 cm-1
Sample technique: Kbr disc
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-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-E
 464.8
 520.7
 572.8
 644.2
 694.3
 732.9
 808.1
 844.8 935.4
1002.9
1029.9
1072.3
1122.5
1182.3
1253.6
1303.8
1429.2
1508.2
1581.51610.5
2794.7
2956.7
3145.7 3307.7
Table 1:  IR spectral study of 4-amino-5-(4-methoxyphenyl)-4H-1, 2, 4-triazole
- 3 - thiol (HAS - E)
N N
N
NH2
O
CH3
SH
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2956
2794
1429
1303
3145
1508
1122
1072
808
1610
1253
1029
3307
732
2975 - 2950
2880 - 2860
1470 - 1420
1385 - 1300
3150 - 3030
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1050-1010
3400-3250
740-640
 Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str. (sym.)
N-H str. (-NH2)
C-S  str.
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0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-1
 468.7
 520.7
 572.8
 594.0
 636.5 669.3
 692.4
 731.0
 800.4
 835.1
 883.3
 935.4
 966.3
1029.9
1076.2
1110.9
1163.0
1180.4
1218.9
1257.5
1284.5
1353.9
1402.2
1429.2
1512.1
1569.9
1608.5
1899.8
2052.1
2324.1
2559.4
2783.1
2835.2
2931.6
3008.7
3103.3
Table 2:   IR spectral study of 4-({[3-mercapto-5-(4-methoxyphenyl)-4H-1, 2,
                 4- triazol-4-yl] imino} methyl (HAS-1)
N N
N
N
O
CH3
SH
OH
   Alkane
  (Methyl)
 Aromatic
 Triazole
2931
2835
1429
1358
3008
1512
1110
1076
835
1608
1257
1029
692
2324
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
3100 - 3030
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1050-1010
700-600
2400-2300
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
S-H str.
Frequency in cm-1
Observed ReportedType  Vibration  mode
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-2
 464.8
 520.7
 572.8
 596.0
 632.6
 667.3
 690.5
 732.9
 800.4
 827.4
 842.8
 883.3
 935.4
1029.9
1074.3
1122.5
1180.4
1255.6
1301.9
1406.0
1425.3
1450.4
1508.2
1568.0
1583.4
1606.6
2048.3
2758.0
2833.2
2933.5
3006.8
3134.13307.7
Table 3: IR spectral study of 4-[{4-methoxy benzylidene} amino]-5-(4-
methoxy phenyl)-4H-1, 2, 4- triazole-3-thiol(HAS-2)
N
N
N
N
O
CH3
SH
O CH3
   Alkane
  (Methyl)
 Aromatic
 Triazole
2933
2833
1450
1301
3006
1508
1122
1074
824
1606
1255
1029
690
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
3100 - 3030
1585 - 1480
1125 - 1090
1080-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
Frequency in cm-1
Observed ReportedType  Vibration  mode
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Table 4:  IR spectral study of 4-[(4-fluorobenzylidene) amino]-5-(4-methoxy
phenyl)-4H-1, 2, 4-triazole-3-thiol (HAS-3)
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-3
 451.3
 474.5
 513.0
 578.6
 611.4
 632.6
 667.3
 732.9
 781.1
 812.0
 829.3
 906.5
 943.1
 972.1
1020.3
1074.3
1178.4
1218.9
1259.4
1288.4
1307.6
1350.1
1398.3
1431.1
1460.0
1498.6
1510.2 1 35.2
1583.4
1610.5
1876.6
1980.8
2327.9
2563.2
2750.3
2841.0
2939.3
3010.7
3085.9
N N
N
N
O
CH3
SH
F
   Alkane
  (Methyl)
 Aromatic
 Triazole
2939
2841
1431
1398
3010
1510
1178
1074
829
1610
1288
1020
667
2327
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
3100 - 3030
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
2300-2400
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
S-H
Frequency in cm-1
Observed ReportedType  Vibration  mode
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Table 5:   IR spectral study of 5-({[3-mercapto-5-(4-methoxyphenyl)-4H-1, 2,
4-triazol-4-yl] imino} methyl)-2-methoxyphenol (HAS-4)
 
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-4
 414.7
 464.8
 520.7
 570.9
 596.0
 675.0
 727.1
 796.5
 827.4
 968.2
1026.1
1076.2
1116.7
1159.1
1249.8
1346.2
1382.9
1425.3
1458.11512.1
1602.7
2756.1
2835.2
2935.5
3230.5
N N
N
N
O
CH3
SH
O
CH3
O H
   Alkane
  (Methyl)
 Aromatic
 Triazole
2935
2835
1458
1382
1512
1116
1076
827
1602
1249
1026
675
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
Frequency in cm-1
Observed ReportedType  Vibration  mode
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Table 6:   IR spectral study of 4-[(4-chlorobenzylidene) amino]-5-(4-methoxy
phenyl)-4H-1, 2, 4-triazol (HAS-5)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-5
 462.9
 513.0
 596.0
 630.7
 678.9
 750.3
 800.4
 829.3
 873.7
 968.2
1020.3
1087.8
1176.51255.6
1353.9
1398.3
1425.3
1479.3
1508.2
1562.2
1591.2
1612.4
1774.4
1903.6
2742.6
2929.7
3099.4
N N
N
N
O
CH3
SH
Cl
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2929
2839
1425
1353
3099
1508
1176
1087
829
1612
1255
1020
678
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
3100 - 3030
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
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Table 7:   IR spectral study of 4-{[4-(dimethylamino) benzylidene] amino}-5-
     (4-methoxyphenyl)-4H-1, 2, 4-triazole-3-thiol (HAS-6)
 
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmP-N(CH3)2
 468.7
 516.9
 572.8
 638.4
 732.9
 802.3
 883.3
 935.4
1024.1
1070.4
1122.5
1176.51251.7
1296.1
1361.7
1429.2
1508.2
1608.5
1890.1
2756.1
2939.3
3124.5
3307.7
N N
N
N
O
CH 3
S H
N
C H 3CH 3
Frequency in cm-1
Observed Reported
Type
 Alkane
  (Methyl)
 Aromatic
 Triazole
2939
1429
1361
1536
1122
1070
802
1608
1251
1024
638
2975 - 2950
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
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Table 8:   IR spectral study of 5-(4-methoxyphenyl)-4-[(3-  nitrobenzylidene)amino]-
                  4H-1, 2, 4-triazole-3-thiol (HAS-7)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-7
 416.6
 462.9
 516.9
 578.6
 609.5
 692.4
 754.1
 804.3
 827.4
 879.5
 970.1
1029.9
1078.1
1124.4
1178.4
1218.9
1263.3
1359.7
1402.2
1429.2
1506.3
1610.5
2754.2
2941.2
3126.4
N N
N
N
O
CH3
SH
N
+
O
-
O
Frequency in cm- 1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2941
2839
1429
1359
1506
1124
1078
827
1610
1263
1029
692
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
    C-O-C str.(sym.)
C-S  str.
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Table 9:   IR spectral study of 4-[(2-chlorobenzylidene) amino]-5-(4-methoxy
phenyl)-4H-1, 2, 4-triazole-3-thiol (HAS-8)
N N
N
N
O
CH3
SH
Cl
Frequency in cm-1
Observed Reported
Type  Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmaks40
 426.2
 520.7
 574.7
 671.2
 734.8
 800.4
 842.8
 910.3
 937.3
1002.9
1029.9
1074.3
1122.5
1155.3
1182.3
1255.6
1301.9
1409.9
1427.2
1452.3
1508.2
1583.4
1608.5
2790.8
2833.2
2933.5
3141.8
3307.7
   Alkane
  (Methyl)
 Aromatic
 Triazole
2933
2833
1452
1508
1122
1074
842
1608
1255
1029
671
2975 - 2950
2880 - 2860
1470 - 1435
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
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Table 10:   IR spectral study of 2-({[3-mercapto-5-(4-methoxyphenyl)-4H-1,
                   2, 4-triazol yl] imino} methyl) phenol (HAS-9)
 
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-9
 476.4
 501.5
 574.7
 609.5
 675.0
 731.0
 829.3
 879.5
 970.1
1026.11178.4
1259.4
1284.5
1361.7
1402.2
1510.2
1610.5
2756.1
2943.2
3105.2
N N
N
N
O
CH3
SH
OH
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2943
1361
3105
1510
1178
829
1610
1259
1026
675
2975 - 2950
1385 - 1350
3100 - 3030
1585 - 1480
1125 - 1090
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
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Table 11:   IR spectral study of 5-(4-methoxyphenyl)-4-{[(1E)-
                    phenylmethylene] amino}-4H-1, 2, 4-triazole-3-thiol (HAS-10)
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS-10
 426.2
 520.7
 574.7
 671.2
 734.8
 800.4
 842.8
 910.3
 937.3
1002.9
1029.9
1074.3
1122.5
1155.3
1182.3
1255.6
1301.9
1409.9
1427.2
1452.3
1508.2
1583.4
1608.5
2790.8
2833.2
2933.5
3141.8
3307.7
N N
N
N
O
CH3
SH
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2933
2833
1452
1508
1122
1074
842
1608
1255
1029
671
2975 - 2950
2880 - 2860
1470 - 1435
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
25
1H NMR SPECTRA
The effect was first noticed in 1902 by P. Zeeman, a physicist, who won a Nobel
Prize for noticing that nuclei of certain atoms behave strongely in a magnetic field.
Fifty years later F. Bloch and E. Purcell, both physicists put this idea to good use by
constructing the first NMR spectrometer. They too received a Nobel Prize for this work.
Nuclear Magnetic Resonance (NMR) spectroscopy is the absorption of
radiofrequency radiation by a nucleus in a strong magnetic field. Absorption of the
radiation causes the nuclear spin to realign or flip in the higher-energy direction.
After absorbing energy the nuclei will reemit RF radiation and return to the lower-
energy state.
This introduction is designed to explain Nuclear Magnetic Resonance
spectroscopy, which is now the main structure determination tool used by organic
chemists. This technique can be used to determine the structures of virtually all organic
compounds, no matter how complex. It is even being used to determine very complex
structures such as enzymes and proteins.
NMR produces a spectrum containing a number of peaks. The heights and
positions of these peaks enables a chemist to very accurately determine what the
carbon-hydrogen framework of an organic molecule is.
Proton Nuclear Magnetic Resonance (1H NMR) Spectroscopy is a powerful
method used in the determination of the structure of unknown organic compounds.
         The principle of NMR is based upon the spin of atomic nuclei in an external
magnetic field. Not all nuclei possess this ability. The main two which are used are the
proton (1H) and an isotope of carbon (13C).
            Instrument : BRUKER Spectrometer (300 MHz)
            Internal reference : TMS
            Solvent : CDCl3/DMSO
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Table 12:   1H NMR spectral study of 4-amino-5-(4-methoxyphenyl)-4H-1, 2,
                     4-  triazole-3-thiol (HAS-E)
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
    1. 3.84 3H singlet Ar-OCH
3
-
2. 6.94-6.99 2H doublet Ar-H(aa’) 8.85
3. 8.95-8.98 2H doublet Ar-H(bb’) 8.86
N
N
N
NH2
SH
O
CH3
a
a'
b
b'
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Table 14:   1H NMR spectral study of 4-[{4-methoxybenzylidene} amino]-5-
                     (4-methoxyphenyl)-4H-1, 2, 4- triazole-3-thiol (HAS-2)
28
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
1. 3.84 3H singlet Ar-OCH
3(M)
-
2. 3.88 3H singlet Ar-OCH
3
    -
3. 6.96-6.99 2H doublet Ar-Haa’        8.7
4. 7.00-7.03 2H doublet Ar-Hdd’        8.7
5. 7.82-7.85 2H doublet Ar-Hbb’        8.7
6. 7.87-7.89 2H doublet Ar-Hcc’        8.7
7. 9.70 1H singlet -CHe=N-    -
8. 13.68 1H broad peak -SH           -
a
a'
b
b'
c
c' d
d'
O CH3
HC
N
N
N
N
SH
O
CH3
e
1H NMR spectral data of 4-[{4-methoxy benzylidene} amino]-5- (4-methoxy
phenyl) -4H-1, 2, 4- triazole-3-thiol (HAS-2)
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Table 15:  1H NMR spectral study of 4-[(4-fluorobenzylidene) amino]-5-(4-
                    methoxyphenyl)-4H-1, 2, 4-triazole-3-thiol (HAS-3)
30
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
     1. 3.86 3H singlet Ar-OCH
3
-
2. 6.97-6.999 2H doublet Ar-Haa’ 8.7
3. 7.17-7.23 2H triplet Ar-Hcc’ -
4. 7.86-7.93 4H multiplet Ar-Hbb’+Hdd’ -
5. 10.05 1H singlet -CHe=N- -
6. 13.78 1H singlet -SHf -
F
HC
N
N
N
N
SH
O
CH3
a
a'
b
b'
c'
c
d
d'
f
e
1H NMR spectral data of 4-[(4-fluorobenzylidene) amino]-5-(4-ethoxyphenyl) -
4H-1, 2, 4-triazole-3-thiol (HAS-3)
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Table 16:   1H NMR spectral study of 5-({[3-mercapto-5-(4-methoxyphenyl)-
4H-1, 2, 4-triazol-4-yl] imino} methyl)-2-methoxyphenol (HAS-4)
32
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
1. 3.84 3H singlet Ar-OCH
3(M)
-
2. 3.91 3H singlet Ar-OCH
3
-
3. 6.93-6.98 3H quartaret Ar-Haa’+He -
4. 7.25-7.30 1H d.doublet Ar-Hd -
5. 7.45-7.46 1H doublet Ar-Hc -
6. 7.85-7.92 2H doublet Ar-Hbb' 9
7. 9.57 1H singlet -N=CH- -
a
a'
b
b'
c
HC
N
N
N
N
SH
O
CH3
O
CH3
OH
f
d
e
1H NMR spectral data of 5-({[3-mercapto-5-(4-methoxyphenyl)-4H-1, 2, 4-
triazol-4-yl] imino} methyl)-2-methoxyphenol (HAS-4)
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Table 17:   1H NMR spectral study of 4-[(4-chlorobenzylidene) amino]-5-(4-
                     methoxyphenyl)-4H-1, 2, 4-triazol (HAS-5)
34
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
    1. 3.86 3H singlet Ar-OCH
3
-
2. 6.97-7.00 2H doublet Ar-Haa’ 8.7
3. 7.41-7.48 2H quartet Ar-Hcc’ -
4. 7.76-7.82 2H triplet Ar-Hdd’ -
5. 7.85-7.88 2H doublet Ar-Hbb’ 9.0
Cl
HC
N
N
N
N
SH
O
CH3
a
a'
b
b'
c'
c
d
d'
1H NMR spectral data of 4-[(4-chlorobenzylidene) amino]-5-(4- methoxy
phenyl)-4H-1, 2, 4-triazol (HAS-5)
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Table 18:   1H NMR spectral study of 5-(4-methoxyphenyl)-4-[(3-  nitrobenzy
lidene) amino] - 4H-1, 2, 4-triazole-3-thiol (HAS-7)
36
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
1. 3.84 3H singlet Ar-OCH
3
-
2. 6.97-7.00 2H doublet Ar-Haa’ 8.7
3. 7.67-7.74 1H multiplet Ar-Hd -
4. 7.84-7.87 2H doublet Ar-Hbb’ 8.7
5. 8.18-8.21 1H doublet Ar-He 8.4
6. 8.31-8.38 1H d.doublet Ar-Hf -
7. 8.67-8.74 1H d.doublet Ar-Hc -
8. 10.51 1H singlet -N=CH- -
9. 13.82 1H singlet -SH -
a
a'
b
b'
c
HC
N
N
N
N
SH
O
CH3
NO 2
g
d
e f
1H NMR spectral data of 5-(4-methoxyphenyl)-4-[(3- nitrobenzylidene) amino] -
4H-1, 2, 4-triazole-3-thiol (HAS-7)
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MASS SPECTRA
Mass spectrometry has been described as the smallest scale in the world, not
because of its size but because of the size of the things it weighs. Mass spectrometry,
also called mass spectroscopy, is an instrumental approach that allows for the mass
measurement of molecules. The five basic parts of any mass spectrometer are: a
vacuum system; a sample introduction device; an ionization source; a mass analyzer;
and an ion detector. Combining these parts a mass spectrometer determines the
molecular weight of chemical compounds by ionizing, separating, and measuring
molecular ions according to their mass-to-charge ratio (m/z). The ions are generated
in the ionization source by inducing either the loss or the gain of a charge (e.g. electron
ejection, protonation, or deprotonation). Once the ions are formed in the gas phase
they can be electrostatically directed into a mass analyzer, separated according to
mass and finally detected. The result of ionization, ion separation, and detection is a
mass spectrum that can provide molecular weight or even structural information.
           Mass spectrometers have become important for a wide range of applications
in the analysis of inorganic, organic, and bio-organic chemicals. Examples include
dating of geologic samples, drug testing and drug discovery, process monitoring in
the petroleum, chemical, and pharmaceutical industries, surface analysis and the
structural identification of unknowns. Further, mass spectrometry is being continually
improved and has recently had significant advances in its application to molecular
biology, where it is now possible to analyze proteins, DNA, and even viruses.
               Mass instrument : GCMS - SHIMADZU-QP2010
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INTRODUCTION
1,2,4-Triazole and their derivatives consist an important class of organic
compounds. Amongst the five membered nitrogen containing heterocycles, the position
of nitrogen atom at 1,2 and 4 activates the ring. The scientists all over the world have
focused their attention to evalute 4-aryltriazole ring system.
The synthesis of these heterocycles has received considerable attention in recent
years. Several methods have been reported in the literatures for the preparation of 4-
aryl triazoles(1-6).
4-aryl triazole and its derivatives possessing a wide spectrum of activities(7-10).
Many workers have reported the different activities of 4-aryl triazoles. Chambers et.al
(11) have investigated 4-aryl triazoles to be useful in the treatment of neurogenerative
disease. Pier et.al.(12) reported as irreversible antagonist at the A3, A2A adenosine
receptor(13). Further, many workers have reported 4-aryl triazoles as aromatic –steroid
sulfatage inhibitors (14), GSKK-3 inhibitors (15), anticancer (16), fungicidal (17), antibacterial
(18), anti-inflammatory (19), PKB ( protein kinas B) inhibitors (20). The triazole derivatives
have also been reported as better therapeutic agents(21).
The scientific literature also stated that the antiviral (22) and antibacterial (23,24)
activities of thiourea derivatives are due to the presence of the –NH-C(S)-NH- function
in the molecule and the changes in this activity depend on the nature of its substituents.
With an aim to synthesise better therapeutic agents, we have investigated some new
4-aryl triazole derivatives which have been described as under.
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EXPERIMENTAL
(1) Synthesis of potassium 4-methoxy benzoic acid hydrazide
dithiocarbamate (HAS-D)
            Part 1, Section I
(2) Synthesis of 5-(4-methoxyphenyl)-4-(4-methylphenyl)-4H-1,2,4-triazole-
3-thiol
A mixture of potassium salt (HAS-D) and p-toludine was heated up to
evolution of H2S gas. DMF was added to this mixture and contents were poured
into ice. The crude product was filtered and crystallized from ethyl alcohol.
Similarly other 4-aryl triazoles were synthesized. The reaction scheme
is as given below:
+ R NH2
Fused
N
N
N
SH
O
CH3
R
O
NH
NH S
S
KO
CH3
-
+
REACTION SCHEME
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Table 1:  IR Spectra of  5-(4-methoxyphenyl)-4-(4-methylphenyl)-4H-1,2,4-
     triazole-3-thiol. (HASD-1)
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHASD-1
 407.0
 487.0
 535.2
 590.2
 637.4
 669.3
 706.9
 717.5
 736.8 79 .5
 811.0
 839.9
 969.2
1021.2
1110.0
1181.3
1255.6
1283.5
1299.91331.8
1393.5
1426.31513.1
1579.6
1611.4
2357.8
2756.1
2932.6
3075.3
N
N
N
SH
O
CH3
CH3
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
Triazole
2932
1426
1331
3075
1513
1110
1021
839
1611
1255
1021
669
2975 - 2950
1470 - 1435
1385 - 1350
3100 - 3030
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
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Table 2: 1H NMR Spectra of  5-(4-methoxyphenyl)-4-(4-methylphenyl)-4H-1,2,4-
     triazole-3-thiol (HASD-1).
    67
 Signal Signal Position Relative No. Multiplicity Inference J
No. (ä ppm) of Protons         In Hz
1. 2.43 3H singlet Ar-CH
3
-
2. 3.78 3H singlet Ar-OCH
3
-
3. 6.77-6.80 2H doublet Ar-Haa’ 9.0
4. 7.16-7.19 2H doublet Ar-Hdd’ 8.1
5. 7.22-7.28 4H d.doublet Ar-Hbb'+Hcc’ -
6. 11.6 1H singlet -SH -
N
N
N
SH
O
CH3
CH3
a b
b'a'
c
c'
d
d'
1H NMR Spectral data of  5-(4-methoxyphenyl)-4-(4-methylphenyl)-4H-1,2,4-
triazole-3-thiol (HASD-1).
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INTRODUCTION
     Thiadiazoles are the compounds containing three carbon atoms, one sulphur
atom, and one nitrogen atom in five member ring. It is parent material for numerous of
chemical compounds including sulfur drugs, biocides, fungicides, dyes, chemical
reaction accelerators. Thiadiazoles and its derivatives are important in the industry of
dyes, photographic chemicals, sulfa drugs, preservative and rubber. Thiadiazoles dyes
contain the color radicals of =C=N- and -S-C= which decide colors to a compound.
Some thiazole derivatives belong to a class of cyclic sulfur organo products containing
sulfur atom (S) and often oxygen (O), nitrogen (N), hydrogen (H), as well as other
elements. Such compounds find application for making biological activitive agents.
Thiazole and its derivatives are also used as thiol flavouring substances.
In 1882, 1,3,4-thiadiazoles was first described by Fischer and further developed
by Busch and co-workers. Literature survey reveals that several workers described
the synthesis of Thiadiazoles(1-4).  Bano and co-workers have synthesized 6-phenyl
amino 1,3,4-thiadiazoles(5). 1,3,4-thiadiazoles have prepared through the intramolecular
Mannich reaction by ian-Xian et al(6).Rune and co-workers have prepared some new
1,3,4-thiadiazoles derivatives(7). 1,3,4-thiadiazole derivatives as non-mutagenic
megazol analogues were synthesized by Samir and co-workers(8). Investigation on the
aromaticity of 1,3,4-thiadiazoles was studied by Safiye Sag and co-workers(9).
Andanappa and workers have synthesised these derivatives as anti tubercular agent(10).
Extensive research has been carried out to enhance the activity and reduce
toxicity of thiadiazole drugs. Various derivatives have resulted in many drugs and exhibit
different biological activities(11-14). Thiadiazoles and its derivatives are used for biological
activities such as antiviral(15), antibacterial(16), antifungal(17) and antituberculous(18).Gabriela
and co-workers have prepared I,3,4-thiadiazole compounds as carbonic anhydrase
inhibitors(19). These compounds are also reported as anti-cancer agent by Nalan and
co-workers(20). Anti-inflammatory activity was reported for thiadiazole by Erhan and
workers(21).
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EXPERIMENTAL
(1)  Synthesis of 3-(4-methoxyphenyl)-6-(4-methylphenyl) [1,2,4]triazolo [3,4-
b] [1,3,4] thiadiazole (HASG-1)
A mixture of P-toluic acid (1.36gm., 0.01mole) and 4-amino-5-(4-
methoxyphenyl)-4H-1, 2, 4- triazole-3-thiol (2.22gm., 0.01mole) in  POCl3 (25ml)
was refluxed for 10 hours. The reaction mixture was  poured onto crushed ice
and thus solid separated out was filtered, washed with water and crystallised
from ethanol. Similarly other aromatic acids have been condensed.
(2)  Synthesis of 3,6-bis(4-methoxyphenyl)-5,6-dihydro[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazole (HASH-1)
A mixture of 4-amino-5-(4-methoxyphenyl)-4H-1, 2, 4- triazole-3-thiol
(2.22gm., 0.01mole), p-anisaldehyde (1.36gm, 0.01mole) and p-toluene
sulphonic acid (P-TsOH)(50mg. in DMF, 50ml) was refluxed for 10 hours. The
reaction was poured onto crushed ice and thus solid obtained was filtered,
washed with water and crystallized from ethanol. Similarly other
aromaticaldehydes have been condedensed.
N
N
N
NH2
SH
O
CH3
+ R-COOH
POCl3
Reflux
R
N
N N
N
S
O
CH3
REACTION  SCHEME
N
N
N
NH2
SH
O
CH3
+
Reflux
R
N
N N
N
H
S
O
CH3
R-CHO
PTS
 HASG
                                                                    HASH
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Table 1:  IR  spectral data of 3-(4-methoxyphenyl)-6-(4-methylphenyl) [1,2,4]triazolo [3,4-
  b] [1,3,4] thiadiazole (HASG-1).
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHASG-1
 414.7
 445.5
 492.8
 595.0 812.0
 830.3
 954.7
 973.0
1025.1
1111.9
1178.4
1256.5
1297.0
1442.7
1465.8
1479.3
1579.6
1611.4
2341.4
2359.7
2849.6
2920.0
N
N N
N
S
O
CH3
CH3
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2920
2849
1442
1579
1112
1025
830
1611
1256
1025
671
2975 - 2950
2880 - 2860
1470 - 1435
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
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Table 2:  IR spectra data of 3,6-bis (4-methoxyphenyl)-5,6-dihydro [1,2,4]triazolo [3,4-b] [1,3,4]
              thiadiazole (HASH-1).
-20.0
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmHAS
 445.5
 509.2
 530.4
 543.9
 556.4
 596.9
 633.6
 676.0
 698.2
 721.3
 736.8
 791.7
 830.3
 840.9
 877.6
 928.7
 950.8
 968.2
1014.5
1079.1
1110.0
1164.9
1179.4
1250.8
1309.6
1353.9
1400.2
1422.4
1466.8
1486.1
1513.1
1565.1
1602.7
2836.1
2933.5
3234.4
N
N N
N
H
S
O
CH3
O CH3
Frequency in cm-1
Observed Reported
Type
   Alkane
  (Methyl)
 Aromatic
 Triazole
2933
2836
1466
1353
1513
1179
1079
830
1602
1250
1014
676
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
1070-1000
835 - 810
1650 - 1580
1350 - 1200
1075-1010
700-600
 Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(sym.)
C-S  str.
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Table 3:  1HNMR spectra 3-(4-methoxyphenyl)-6-(4-methylphenyl)[1,2,4]triazolo [3,4- b] [1,3,4]
              thiadiazole (HASG-1).
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1HNMR spectral data 3-(4-methoxyphenyl)-6-(4-methylphenyl)[1,2,4]triazolo [3,4-b] [1,3,4]
thiadiazole (HASG-1).
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
1. 2.46 3H singlet Ar-CH
3
-
2. 3.90 3H singlet Ar-OCH
3
-
3. 7.06-7.09 2H doublet Ar-Haa’ 9.1
4. 7.34-7.37 2H doublet Ar-Hcc’ 8.1
5. 7.82-7.85 2H doublet Ar-Hdd’ 8.1
6. 8.34-8.37 2H doublet Ar-Hbb' 8.7
N
N N
N
S
O
CH3
CH3
a
a'
b
b'
c
c'
d
d'
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Table 4:  1H NMR spectra of 3,6-bis(4-methoxyphenyl)-5,6-dihydro[1,2,4]triazolo [3,4-b] [1,3,4]
   thiadiazole (HASH-1).
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1H NMR spectral data of 3,6-bis(4-methoxyphenyl)-5,6-dihydro [1,2,4]triazolo [3,4-b] [1,3,4]
thiadiazole (HASH-1).
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
1. 3.86 3H singlet Ar-OCH
3(M)
-
2. 3.89 3H singlet Ar-OCH
3
-
3. 6.96-6.99 2H doublet Ar-Haa’ 8.7
4. 7.00-7.03 2H doublet Ar-Hdd’ 8.7
5. 7.58 1H singlet -NH -
6. 7.83-7.86 2H doublet Ar-Hbb' 8.7
7. 7.88-7.91 2H doublet Ar-Hcc’ 8.7
8. 9.74 1H singlet -CHe -
N
N N
N
H
S
O
CH3
CH3
a
a'
b
b'
c
c'
d
d'
e
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INTRODUCTION
Heterocyclic compounds are predominant among the types of compounds used
as pharmaceutical, agrochemical and veterinary products. One of the most useful class
in this category is pyrazole. The pyrazole ring consists of a doubly unsaturated five
membered ring containing two adjacent nitrogen atoms. In 1883,  Knorr (1,2) first
synthesized a compound by the reaction of ethyl acetoacetate with phenyl hydrazine,
which yields 1-phenyl-3-methyl-5-pyrazoline. The name pyrazole was given to such
compounds because the nucleus was derived from pyrrole by replacement of carbon
by nitrogen(3). Much research has been carried out with the aim to find the therapeutic
values of pyrazole moiety, since their discovery(4-6). Various pyrazole and its derivatives
have been used in many drugs(7-9).
Different methods of preparation of pyrazoles are available in literature.  Palmey
synthesized two structurally isomeric pyrazoles by the reaction of the substituted
hydrazines with 1,3-dicarbonyl compounds(10). By the reaction of ethylacetoacetate
with aryl hydrazine hydrate also, Esribano et al synthesized some pyrazoles(11). Jacobs
reported the synthesis by the reaction of acetylene with diazomethane(12) whereas Singh
and Ojha synthesized pyrazoles by the reaction of ethylacetoacetate with aryl
hydrazines(13). Some workers reported synthesis by the reaction of acetonitrile
derivatives with  (DMF-DMA)(14) whereas others synthesized by the cyclocondensation
of monosubstituted hydrazines with enaminones afforded pyrazoles(15).
Pyrazole derivatives were prepared and tested for a variety of biological activities
such as antitumor(16,17), anticancer(18), antiviral(19), anti-inflammatory(20), antiepileptic(21),
anti HIV (18) etc. Many pyrazoles are known to be used as antiproliferature agent (22),
protein kinase inhibitors (23), herbicidal (24), CNS depressant (25), antiulcer (26),neurotonsin
receptor (27), immino suppressants (28) etc. Freddy et al. reported the biological activity
of 4-5-dihydro-3-phenyl-1H-pyrazole(29). Shimzo and co-workers have also synthesized
some pyrazole derivatives and reported their herbicidal activity(30). Feid-Allah-Hassan
reported antidiabetic and antibacterial activity of some other pyrazoles(31). El-Emery
et al. synthesized 1, 3, -diphenyl pyrazole derivatives and reported their variety of
89
biological activity(III)(32).  Edgardo et al.  reported the glycine transport-2-inhibitors activity
of some pyrazoles(33). Some pyrazole derivatives have synthesized as a neuropeptide
T5 receptor antagonists by Nagaaki Sato et al
(34). Recently,  Wilst et al. discovered
pyrazole as potential glucocorticoid receptor ligand(35) whereas Prasanna and co-
workers also reported pyrazoles as COX-2 inhibitors(36)
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INTRODUCTION
The chemistry of chalcones has generated intensive scientific studies throughout
the world. Specially interest has been focused on the synthesis and biodynamic activities
of chalcones. The name “ Chalcones” was given by Kostanecki and tambor(1). These
compounds are also known as benzalacetophenones or benzylidene acetophenones. In
chalcones, two aromatic rings are linked by an aliphatic three carbon chain. The presence
of a,b-unsaturated carbonyl group gives good biological activity. Chalcone bears a very
good synthon so that variety of novel heterocycles with good pharmacological profile can
be designed.
Different methods are available for the preparation of chalcones (2-4). The most
convenient methods is the Claisen-Schimdt condensation of equimolar quantities of a aryl
methyl ketones with aryl aldehyde in the presence of alcoholic alkali(5). Chalcones are used
to synthesise several derivatives like cyanopyridines, pyrazolines, isoxazoles, pyrimidines,
having different heterocyclic ring systems(6-9).
With a variety of biological activity, chalcones are useful in pharmaceuticals. They
are associated with different biological activities like insecticidal(10), anticancer(11), anti-
inflammatory(12), bactericidal(13), fungicidal(14), antiviral(15), antitumor(16), antimalarial(17) and
antiulcer(18). Literature shows that lieochalcone and oxygenated chalcone has strong
antileishmanial activity(19,20). It is reported that chalcones exhibited potent activity against
human malarial parasite(21). Many workers have reported the different pharmacological
activities of chalcones and its derivatives(22-25). The antibacterial activities of some substituted
chalcones have been studied by Modi et al.(26). De Vincenzo et al. reported antiflammatory
activity of som e chalcone derivatives(27). Aldose reductase inhibitor activity of chalcone
derivatives has also been reported by Okuyama et al.(28).Toru et al.(29) reported anticancer
activities of chalchones. Seo et al. reports the chalcones as a-glucosidase inhibitors(30).
Antiplasmodial activity of ferrocenyl chalcones was reported Xiang et al.(31). Bhat and co-
workers reported cytotoxic properties of chalcones and their derived pyrazoles(32).
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EXPERIMENTAL
Synthesis of 1-aryl-3-(1',N-phenyl-3'-p-nitrophenyl pyrazol-4'-yl)-
2-propene-1-ones
[A] Synthesis of N-aminophenyl-a-methyl-p-nitrophenyl azomethine
A mixture of phenylhydrazine (1.08 g, 0.01M) and p-nitrophenyl
aceto phenone (1.65 g, 0.01M) in absolute ethanol was refluxed in water
bath for 2 hrs. in presence of 1 ml glacial acetic acid. The crude product
was isolated and crystallised from absolute alcohol.
[B] Synthesis of 1,N-phenyl-3-p-nitrophenyl-4-formyl pyrazole
N-Aminophenyl-a-methyl-p-nitrophenyl azomethine (2.53g, 0.01M)
was added in mixture of Vilsmeir-Haack reagent (prepared by dropwise
addition of 3 ml POCl3 in ice cooled 25 ml DMF). and refluxed for 5 hrs.
The reaction mixture was poured into ice followed by neutralization using
sodium bicarbonate. Crude product was isolated and crystallised from
ethanol.
[C] Synthesis of 1-(p-Anisyl)-3-(1'-N-phenyl-3'-p-nitrophenyl pyrazol-
4'-yl)-2-propene-1-one (AS-1a)
To a well stirred solution of 1,N-phenyl-3-p-nitrophenyl-4-formyl-
pyrazole (2.93gm, 0.01M) and p-methoxy-acetophenone (1.5 g, 0.01M)
in ethanol (25 ml), 40% KOH added till the solution become basic. The
reaction mixture was stirred for 24 hrs. The contents were poured into
ice, acidified, filtered and crystallised from ethanol.
Similarly, other substituted chalcones have prepared. The physical
data are recorded in Table 6.
a
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                                                     REACTION SCHEME
N
N
O
R
NO2
N
N
CHO
NO 2
R CH3
O
40% KOH
Vilsmeier-Haack
Formylation
NH
N
NO 2
CH3
Cat. gla. CH3COOH
Abs. C 2H5OH
NO 2
CH3
O
NH
NH2
+
        R= Aryl
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0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmAS-P
 489.9
 682.8
 711.7
 754.1
 783.0
 808.1
 858.3
 960.5
1014.5
1064.6
1107.1
1207.4
1294.1
1344.3
1423.4
1523.7
1600.8
1681.8
2783.1
3425.3
N
N
CHO
NO2
 Table 1:  IR Spectral study of 1,N-phenyl-3-p-nitrophenyl-4-formyl pyrazole
Alkane
(Methyl)
Aromatic
Pyrazole
moiety
Pyrazole
aldehyde
Frequency in cm-1
Observed Reported
2975 - 2950
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
860 - 810
1650 - 1580
1350 - 1200
1750 - 1650
2800-2750
Type  Vibration  mode
C-H str.(asym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
 C=O str.
 C-H str.
2937
1423
1344
1524
1107
858
1601
1294
1682
2783
96
Table 2: IR Spectral study of 1-anisyl-3-[1’, N-phenyl-3’-p-nitrophenyl-pyrazol-
                4’-yl]-2-propene-1-one (AS-1a)
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmAS-1
 431.1
 597.9
 672.1
 710.7
 750.3
 806.2
 862.1
 961.4
1028.0
1108.0
1173.6
1222.8
1267.1
1317.3
1341.4
1418.5
1441.7
1510.2
1598.9
1657.7
2837.1
3377.1
N
N
O
NO2
H3CO
Alkane
(Methyl)
Aromatic
Pyrazole
moiety
Ether
Chalcone
Frequency in cm-1
Observed Reported
2880 - 2860
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
860 - 810
1650 - 1580
1350 - 1200
1275-1200
1075- 1020
1750-1650
Type  Vibration  mode
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-Cstr.(asym).
C-O-C(sym.)
C=O str.
2837
1441
1341
1510
1108
862
1600
1317
1267
1028
1658
97
Table 3:  1H NMR spectra of  1-anisyl-3-[1’, N-phenyl-3’-p-nitrophenyl-pyrazol-
                 4’-yl]-2-propene-1-one (AS-1a)
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1H NMR spectral data of 1-anisyl-3-[1’, N-phenyl-3’-p-nitrophenyl-pyrazol-4’-
yl]-2-propene-1-one (AS-1a)
N
N
O
NO2
H3CO
b c
c'b' x
d
e
e'
d'
h
i
f'f
g
g'
a
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
     1. 3.89 3H singlet Ar-OCH
3
-
2. 6.96-6.99 2H doublet Ar-Hgg' 8.7
3. 7.39-7.42 2H multiplet Hh&Hi -
4. 7.50-7.55 2H triplet Ar-Hbb' -
-
5. 7.79-7.82 3H doublet Ar-Hdd'+Ha 9.0
6. 7.91-7.94 2H doublet Ar-Hee' 8.7
7. 7.98-8.01 2H doublet Ar-Hcc' 9.0
8. 8.33-8.36 2H doublet Ar-Hff’ 8.6
9. 8.38 1H singlet Hx -
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INTRODUCTION
Pyrazolines are well known for their varied applications in the field of medicine.
Amongst nitrogen containing five membered heterocycles, pyrazolines have proved
to be the most useful framework. In 1967, Jarobe(1,2) reviewed the chemistry of
pyrazolines and studied their biological and industrial applications.
The preparation of pyrazoline derivatives have been reported in the literature(3-7).
Epoxidation of chalcones have epoxy ketones which reacts with hydrazine and phenyl
hydrazine to give pyrazolines(8). It can be constructed by the cyclo condensation of
chalcones with hydrazine hydrate(9).  Desaea and coworkers(10) reported the synthesis
of some new pyrazoline derivatives. Padya et al. reported that 2-pyrazoline can be
prepared by the condensation of chalcone dibromide with hydrazines(11). Some 3,5-
diphenyl-2-pyrazolines were also synthesised by Palaska et al.(12). Kucukguzel and
Rollas reported the  preparation of 4-arylhydrozono-2-pyrazoline-5-ones(13). Recently,
Ji and Shi have also synthesised some novel benzothiazoyl pyrazolines(14).
2-pyrazolines are also reported to be associated with different biological
activities like antibacterial(15), antifungal(16), antidepresent(17), insecticidal(18), anti-
inflmmatory(19), herbicidal(20), tranquilizing (21), anticonvulsant (22), antidiabetic (23),
antiandeogenic(24), antiamoebic(25) etc. Garg and Singh(26) reported the antidiabetic
activity of these compounds. Hans et al. reported the tranquilizing property of some
pyrazolines(27). Diuretic and hypoglycemic properties of some pyrazolines have also
been reported(28,29).  Richard et al.(30) studied the anti-inflammatory and antiarthritic
activity of some derivatives of pyrazolines.The antimicrobial activity of 3-(2-acetoxy-4-
methoxyphenyl)-5-(substituted phenyl)-pyrazolines was reported by Sonare et al. (31).
Shivnanda et al.(32) also reported antibacterial activity whereas Palska et al. reported
the antidepressant activity of some pyrazolines(33). Carrion et al. have reported the
iNOS/nNOS inhibitory activities of new benzopyrazolines derivatives(34). Ucar et al.
reported pyrazolines as cholinstearase and selective monoamine oxidase B inhibitiors
for the treatment of Parkinson’s and Alzheimer’s diseases(35).
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EXPERIMENTAL
Synthesis of 3-aryl-5-(1',N-phenyl-3'-p-nitrophenyl pyrazol-4'-yl)-
          pyrazolines
[A] Synthesisof N-aminophenyl-a-methyl-2-p-nitrophenyl-azomethine
 Section-I (A).
[B] Synthesis of 1,N-phenyl-3-p-nitrophenyl-4-formyl pyrazole
 Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-(1'-N-phenyl-3'-p-nitrophenyl-pyrazol-
4'-yl)-2-propene-1-one
 Section-I (C).
[D] Synthesis of 3-(p-Anisyl)-5-(1'-N-phenyl-3'-p-nitrophenylpyrazol-
4'-yl)-pyrazoline
A mixture of 1-(p-anisyl)-3-(1',N-phenyl-3'-p-nitrophenyl-pyrazol-
4'-yl)-2-propene-1-one (4.20g, 0.01M) in 25 ml of absolute alcohol, add
hydrazine hydrate (0.5g, 0.01M) was refluxed in water bath at temp. 80-
90oC for 8 hrs. The reaction mixture was poured into ice. The product
was isolated and crystallised from ethanol.
Similarly other substituted pyrazolines have been prepared. The
physical data are recorded in Table 4.
N
N
NO2
N
NH
R
N
N
O
R
NO2
NH2.NH2.H2O
REACTION  SCHEME
               R=Aryl                                                                     R=Aryl
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Table 1:  IR spectral study of 3-anisyl-5-[1’,N-phenyl-3’-p-nitrophenyl-pyrazol-
     4’-yl]-pyrazoline(AS-3a)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmAS-3
 416.6
 509.2
 607.5
 651.9
 692.4
 761.8
 839.0
 962.4
1033.8
1109.0
1174.6
1232.4
1342.4
1512.1
1550.7
1598.9
2839.0
2916.2
3307.7
N
N NO 2
N
NH
OCH 3
Alkane
(Methyl)
Aromatic
Pyrazole
moiety
Ether
Pyrazoline
Frequency in cm-1
Observed Reported
2975 - 2950
2880 - 2860
1385 - 1350
1585 - 1480
1125 - 1090
860 - 810
1650 - 1580
1350 - 1200
1275-1200
1075- 1020
1627-1550
3450-3250
Type  Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-Cstr.(asym).
C-O-C(sym.)
C=N  str.
2916
2839
1342
1109
839
1599
1342
1232
1034
1551
3308N-H str.
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Table 2:  1H NMR spectra of 3-anisyl-5-[1’,N-phenyl-3’-p-nitrophenyl-pyrazol-
     4’-yl]-pyrazoline (AS-3a)
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1H NMR spectral data of  3-anisyl-5-[1’,N-phenyl-3’-p-nitrophenyl-pyrazol-
4’-yl]-pyrazoline (AS-3a)
N
N
NO2
N
NH
OCH3
b
c
c'
b'
x
d e
e'd'
h
i
f'
f
g
g'
a
j
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
1. 2.57 1H d.doublet h -
2. 3.44-3.53 1H d.doublet i -
3. 3.81 3H singlet Ar-OCH
3
-
4. 5.11-5.17 1H d.doublet j -
5. 6.87-6.90 2H doublet Ar-Hgg' 8.7
6. 7.31-7.34 1H triplet Ar-Ha -
7. 7.45-7.50 2H triplet Ar-Hbb’ -
8. 7.57-7.60 2H doublet Ar-Hdd'   8.77
9. 7.81-7.83 2H doublet Ar-Hee' 7.8
10. 7.89 1H singlet -NH -
11. 8.04-8.07 2H doublet Ar-Hcc’ 9
12. 8.28-8.31 2H doublet Ar-Hff’ 8.7
      13. 8.37                 1H                 singlet  Hx -
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INTRODUCTION
Pyridine also belongs to an important class of heterocyclic compounds, which
are useful in various fields such as medicine, agriculture and industrial chemistry. Some
pyridine derivatives are active in the metabolism of body and are also used as a
denaturant for antifreeze mixtures, as a dyeing assitant in textiles(1) and fungicides(2).
Some of them are also used as synthetic intermediates whereas some occurs as a
component of structure of coenzymes(3-6).
Cyanopyridines, the derivatives of pyridine can be prepared by the different
reported methods (7-11). Samour (12) and co-workers have prepared substituted
cyanopyridines by the condensation of chalcones with malanonitrile in presence of
ammonium acetate.Sakurai and Midorikwa(13,14) have reported that malanonitrile when
reacts with a ,b-unsaturated ketones, it gives 2-amino-3-cyano-4-6-disubstituted
pyridines.  M. Kanded reported some other derivatives of pyridine(15).
Due to varied therapeutic activity, cyanopyridine derivatives have been used
extensively in medicines (16-18). It possess different activities like analgesic (19),
antihypertensive(20), antibacterial(21), anticonvulsant(22) etc. Latif and coworkers(23) have
reported the antibacterial and antifungal activity of 2-amino-3-cyano-4,6-disubstituted
pyridines. Teu and coworkers have also shown cyanopyridines as agrochemical
fungicides(24). Gadaginamath and co-workers(25) have synthesized various cyanopyridyl
derivatives and documentated their variety of biological activities.The anti infammatory
activity of 3-cyanopyridines has also been reported(26). The pharmacological activity of
these cyanopyridine have been reported by Galil and Amr(27). Hammana Abou and co-
workers have studied the anticancer and anti-HIV activity of 3-cyanopyridines(28).
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EXPERIMENTAL
Synthesis 2-methoxy-3-cyano-4-[1',N-phenyl-3'-p-nitrophenyl pyrazole-
4'-yl]-6-aryl pyridines
[A] Synthesis of N-aminophenyl-a-methyl-p-nitrophenyl-azomethine
Section-I (A).
[B] Synthesis of 1,N-phenyl-3-p-nitrorophenyl-4-formyl pyrazole
Section-I (B).
[C] Synthesis of 1-phenyl-3-(1'-N-phenyl-3'-p-fluorophenyl-pyrazol-4'-
yl)-2-propene-1-one
Section-I (C).
[D] Synthesis of 2-methoxy-3-cyano-4-[1',N-phenyl-3'-p-nitrophenyl-
pyrazol-4'-yl]-6-anisyl-pyridine
A mixture of 1-anisyl-3-(1',N-phenyl)-3'-p-nitrophenyl pyrazol-4'-
yl)-2-porpene-1-one (4.20 g, 0.01M), malononitrile (0.66 g, 0.01 M) and
sodium methoxide (10 ml) (6.61g, 0.08M) dissolved in absoulte alcohol
was refluxed for 10 hrs. in water bath at temp 70oC. The reaction product
was poured into ice, crude product was isolated, crystallized from
ethanol.
Similarly other cyanopyridines have been obtained. The physical
data are recorded in Table 4.
REACTION SCHEME
     R = Aryl
N
N
O
R
NO2
CH2.(CN) 2
N
N
NO2
N
R
H3CO
N
NaOMe
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Table 1:  IR spectral study of  2-methoxy-3-cyano-4-[1',N-phenyl-3'-p-
     nitrophenyl-pyrazol-4'-yl]-6-anisyl-pyridine (AS-5a)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmAS-5
 416.6
 439.7
 462.986 0
 532.3 690.5
 758.0
 991.3
1029.9
1112.9
1149.5
1174.6
1213.1
1244.0
1298.0
1340.4
1413.7
1508.2
1539.1
1558.4
1585.4
2214.1
3419.6
N
N
NO 2
N
H 3CO
N
OCH 3
Alkane
(Methyl)
Aromatic
Pyrazole
moiety
Ether
Pyridine ring
Frequency in cm-1
Observed Reported
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1000
835 - 810
1650 - 1580
1350 - 1200
1275-1200
2240-2120
1650-1550
1585-1480
Type  Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-Cstr.(asym).
C-N str.
C=N  str.
C=C str.
2916
2839
1413
1340
1539
1029
839
1585
1244
1213
2214
1558
1508
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Table 2:  1H NMR spectra of 2-methoxy-3-cyano-4-[1',N-phenyl-3'-p-
      nitrophenyl-pyrazol-4'-yl]-6-anisyl-pyridine (AS-5a)
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1H NMR  spectral data of 2-methoxy-3-cyano-4-[1' ,N-phenyl-3' -p-
nitrophenyl-pyrazol-4'-yl]-6-anisyl-pyridine (AS-5a)
N
N
NO2
N
H3CO
N
OCH3
b
c
c'
b'
x
d e
e'd'
a
f'
f
g
g'
h
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
1. 3.86 3H singlet Ar-OCH
3
-
2. 4.19 3H singlet Pyridinering -
Ar-OCH
3
3. 6.95-6.98 2H doublet Ar-Hgg’ 9.9
4. 7.36 1H singlet Ar-Hh -
5. 7.38-7.43 1H triplet Ar-Ha -
6. 7.52-7.58 2H triplet Ar-Hbb’ -
7. 7.78-7.81 2H doublet Ar-Hdd’ 7.2
8. 7.87-7.90 2H doublet Ar-Hee’ 7.8
9. 7.94-7.97 2H doublet Ar-Hcc’ 8.7
10. 8.21-8.24 2H doublet Ar-Hff' 9
11. 8.59 2H singlet Ar-Hx -
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INTRODUCTION
Thiazolidinones are derivatives of thiazolidines with carbonyl group at position
2, 4 or 5. These heterocyclic compounds have been extensively explored for their
applications in the field of medicine. Some of these are an integral part of medicinally
important compounds like penicillin’s and some antiradiation drugs.
Preparations of 4-thiazolidones are narrated in literature(1-9). Shah and Trivedi(10)
synthesized thiazolidinone from 4-aryl thiosemicarbazones by condensing them with
chloroacetic acid, a-bromopropioinic acid and a-bromo phenyl acetic acids. Nath et
al have prepared 4-thiazolidinone by cyclization of N-aryl-N’-(2’-pyridyl)thio carbamide
with chloroacetic acid(10)’. Some new thiazolidinone derivatives have been synthesized
by Saeda et al.(11). Hassan et al(12) also synthesized some thiazolidinones. Recently,
some new thiazolidinone derivatives have also been reported(13-17).
Many Thiazolidinones are known to possess different activities like antitumor(18),
antitubercular(19,20), anti-HIV and anticancer(21), antiprolifature(22), antiviral(23) antifungal(24,25),
anti-inflammatory(26) etc. Some thiazolidinones are known to have antithelmintic(27),
cardiovascular(28), and analgesic(29), hypnotic(30,31) properties. Monforte et al.(32) studied
the antitumor activity of some thiazolidinones. El-Shafi and Hassan(33) reported that
some thiazolidinone derivatives can act as local anaesthetic. The antitubercular studies
of some other thiazolidinones were also done(34,35). Rao reported the antifundal activities
of some thiazolidinones(36).  Pawar and co-workers(37) have studied invitro anti bacterial
activity of some 4-thiazolidinone derivatives. Antioxidant activity of thiazolidinones have
been studied by Mei-Hsiu Shih(38).
Thus, the important role displayed by thiazolidinone and its derivatives for
various therapeutic and pharmaceutical activities prompted to synthesize some
arylidene derivatives.
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EXPERIMENTAL
Synthesis of 2-arylimino-3,N-aryl-5-(1',N-phenyl-3'-p-nitrophenyl-4'-
pyrazolylmethino)-4-thiazolidinones
[A] Preparation of N1, N3-Bis-p-tolyl thiourea
In a round bottom flask, a mixture of p. toludine (0.2M), carbon
disulphide (7ml, 0.01M) and absolute alcohol for 5-6 hrs. at temp 40oC.
On completion of reaction, the excess of carbon disulphide and alcohol
was removed by distillation. The product was treated with hydrochloric
acid to remove excess of amine present and crude product was isolated
and crystallised from ethanol.
[B] Preparation of 2-Tolylimino-3-tolyl-5H-4-thiazolidinones
A solution of N 1, N3-bis-p-tolyl thiourea (0.01M) and chloroacetic
acid (0.94g, 0.01M) in glacial acetic acid (15 ml) was refluxed with fused
sodium acetate (1.25g, 0.015M) for 5 hrs. The reaction product was
poured in water, kept overnight, crude product was isolated and
crystallised from ethanol.
[C] Preparation of 2-(p-Tolylimino)-3-(p-tolyl)-5-(1',N-phenyl-3'-p-
nitrophenyl-4'-pyrazolylmethino)-4-thiazolidinone
A mixture of 2-(p-tolylimino)-3-(p-tolyl)-5H-4-thiazolidinone (2.69g,
0.01M) 1,N-phenyl-3-p-fluorophenyl-4-formyl pyrazole (2.93g, 0.01M)
and fused sodium acetate (1.25g, 0.015M) was refluxed in glacial acetic
acid (15 ml) for 4-5hrs. at temp 120oC. cooled, poured into water and
treated with ammonia to remove excess of glacial acetic acid. The
product was isolated and crystallised from ethanol.
Similarly other substituted thiazolidinones have been prepared.
The physical data are recorded in Table 4.
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 Table 1:  IR spectral study of 2-(p-Tolylimino)-3-(p-tolyl)-5-(1',N-phenyl-3'-
     p-nitrophenyl-4'-pyrazolylmethino)-4-thiazolidinone (AS-7a)
0.0
20.0
40.0
60.0
80.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmAS-7
 548.7
 624.9
 651.9
 687.6
 711.7
 735.8
 757.0
 798.5
 831.3
 886.2
 956.6
1029.9
1106.1
1148.5
1219.9
1251.7
1298.0
1337.5
1402.2
1440.7
1507.3
1536.2
1598.9
1634.6
1718.5
2839.0
S
N
N
N
NO 2
N
O
CH3
CH3
Alkane
(Methyl)
Aromatic
Pyrazole
ring
Thiazolidinone
ring
Frequency in cm-1
Observed Reported
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
1070-1000
860 - 810
1650 - 1580
1350 - 1200
1760-1655
1650-1590
700-600
Type  Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C=Ostr.(asym).
C=N  str.
2916
2839
1440
1337
1536
1106
1029
831
1634
1251
1718
1598
687C-S-C str.
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Table 2:  1H NMR spectra of 2-(p-Tolylimino)-3-(p-tolyl)-5-(1',N-phenyl-3'-
    p-nitrophenyl-4'-pyrazolylmethino)-4-thiazolidinone (AS-7a)
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1H NMR spectral data of  2-(p-Tolylimino)-3-(p-tolyl)-5-(1',N-phenyl-3'-
p-nitrophenyl-4'-pyrazolylmethino)-4-thiazolidinone (AS-7a)
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
1. 3.82 3H singlet Ar-OCH
3(a)
-
2. 3.84 3H singlet Ar-OCH
3(b)
-
3. 6.92 4H singlet Ar-Hgg’+Hhh’ -
4. 7.02-7.05 2H doublet Ar-Hdd’ 9.0
5. 7.36-7.42 3H multiplet Ar-Hee'+Ha -
6. 7.49-7.54 2H triplet Ar-Hbb' -
7. 7.74-7.78 3H triplet Ar-Hj+Hcc’ -
8. 7.86-7.89 2H doublet Ar-Hff’ 8.7
9. 8.13 1H singlet Hx -
10. 8.32-8.35 2H doublet Ar-Hii’ 9.0
S
N
N
N
NO 2
N
O
O
CH3
O
CH3
b
c
c'
b'
x
d
e
e'
d'
a
j
f
g
g'
f'
i'
h'
i
h
(a)
(b)
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Heterocyclic compounds have a broad array of biological activity but their
synthesis can be sometimes very challenging for industrial applications (low yields
and very low reaction temperatures). Therefore it may be interesting to find new
procedures in order to achieve better yields and better reaction conditions.
The research on the chemistry of pyrazoles has been a focus of attention for
chemists for several years; due to their wide spread diversified biological activities.
Considering the increasing importance of pyrazole nucleus, the synthesis of some
pyrazolines have been done.
Pyrazolines have been reported to show a broad spectrum of biological
activities including antibacterial(1), antifungal(2), anti-inflammatory(3) and antidepressant
activities.(4) Pyrazole motifs are found in a variety of kinase inhibitors (5).This
characteristic suggeste that a pyrazole would make a good template for a lead
generation library.  This prompted us to synthesize various substituted pyrazoline
derivatives using the Microwave-assisted (MW) method,Ultrasound irradiation (US)
and Conventional thermal (Con.) method.
The microwave region of the electromagnetic spectum lies between 1 cm and
1 m, most domestic and commercial microwave instruments operate at 2.45 GHz.
When a molecule is irradiated with microwaves it rotates to align itself with the applied
field. The frequency of molecular rotation is similar to the frequency of microwave
radiation and consequently the molecule continually attempts to realign itself with the
changing field and energy is absorbed. It is particularly convenient that qualitatively,
the larger the dielectric constant the great the coupling with microwaves. Thus solvents
such as water, methanol, DMF, ethyl acetate, acetone, chloroform, acetic acid and
dichloromethane are all heated when irradiated with microwaves.
In the last few years Microwave-induced Organic Reaction Enhancement
(MORE) chemistry has gained popularity as a non-conventional technique for rapid
organic synthesis(6). Microwave-assisted synthesis has a large impact on synthetic
organic chemistry, in particular the medicinal/combinatorial chemistry communities.
INTRODUCTION
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Many researchers have reported the synthetic utility of MORE chemistry in routine
organic synthesis(7-9). Compared to traditional processing of organic synthesis,
microwave-enhanced chemistry saves significant time and very often improves
conversions, clean product formation.
It can be termed as ‘e-chemistry’ because it is easy, effective, economical and
eco-friendly and is believed to be a step towards green chemistry. Further, it offers low
cost with simplicity in processing and handling(10). By this method, one can also develop
new reaction conditions.
In 1986, Gedye and co-workers first reported the utilization and advantages of
microwave irradiation for organic synthesis(11,12) and studied  different types of
reactions(11). Later on, this technique has been used to promote a variety of chemical
reactions such as additions, cycloadditions, substitutions, eliminations, fragmentations
etc(12-19).
On the other side, ultrasound waves are known for their wide applications in
various fields like life sciences, medical, cleaning, sonar, electronics, agriculture,
oceanography, material science etc(20-24). Further, these waves prove to be important
in synthetic organic chemistry(25-27) by lowering the reaction temperature and reaction
time(28). By using these waves, yield can be increased(29) and one can avoid the use of
phase transfer catalysts in chemical reactions(30).
Ultrasounds have been used in chemistry for the past thirty years. These waves
have proven to enhance reactions yields along with more convenient reactions
conditions, especially in hetergeneous systems. Literature survey shows that few
workers synthesized some compounds using ultrasonic techniques( 31-34).
Therefore, our research deals with sonochemistry and its application to the
synthesis of heterocycles. For instance, some widely used biologically active
compounds have a heterocyclic skeleton and are currently prepared at very low
temperatures with a moderate yield.
In the present chapter, some pyrazolines have been synthesized by concentional
method, microwave technique and by using ultrasound waves.
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EXPERIMENTAL
Synthesis of  1,N-acetyl-3-aryl-5-(1',N-phenyl-3'-p-nitrophenyl pyrazol-
4'-yl)-pyrazolines
[A] Synthesis of N-aminophenyl-a-methyl-p-nitrophenyl azomethine
Section-I (A).
[B] Synthesis of 1,N-phenyl-3-p-nitrophenyl-4-formyl pyrazole
Section-I (B).
[C] Synthesis of 1-(anisyl)-3-(1'-N-phenyl-3'-p-nitrophenyl pyrazol-4'-yl)-2
propene-1-one
Section-I (C).
[D] Synthesis of 1,N-acetyl-3-(p-anisyl)-5-(1',N-phenyl-3'-p-nitrophenyl
pyrazol-4'-yl) pyrazoline
To a mixture of 1-(p-anisyl)-3-(1',N-phenyl-3'-p-nitrophenyl-pyrazole-4'-
yl)-2-propene-1-one (4.20g, 0.01M) in 25 ml of absolute alcohol,   hydrazine
hydrate (0.5g, 0.01M) and glacial acetic acid (10 ml ) was added, the contents
were refluxed for 10 hrs. at temp 120oC. The reaction mixture was then poured
into ice. The product was isolated and crystallised from ethanol.
Similarly, other substituted pyrazolines have also been prepared. The
physical data are recorded in Table 1.
[E] Synthesis of 1,N-phenyl-3-(p-anisyl)-5-(1’,N-phenyl-3’-p-nitorphenyl
pyrazol-4’-yl)-pyrazoline
To a mixture of 1-(p-anisyl)-3-(1',N-phenyl-3'-p-nitrophenyl-pyrazol-4'-yl)-
2-propene-1-one (4.20gm, 0.01M) in 25 ml of absolute alcohol add phenyl
hydrazine (1.08g, 0.01M) was added in presence of basic catalyst like piperidine
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and refluxed for 12 hrs. at temp 70oC. The reaction product was poured into
ice. The product was isolated and crystallised from ethanol
[F] Synthesis of 1,N-acetyl-3-(p-anisyl)-5-(1',N-phenyl-3'-p-nitrophenyl
pyrazol-4'-yl) pyrazolines using microwave induced synthesis
A mix of 1-anisyl-3-(1',N-phenyl-3'-p-nitrophenyl-pyrazol-4'-yl)-2-propene-
1-one (3.98g, 0.01M), hydrazine hydrate (0.5g, 0.01M) and glacial acetic acid
(15 ml) was irradiated in a Q-Pro-M Microwave oven (220 VAC, 60Hz) [Questron
Technologies Corporation-CANADA] at 120oC for 9 min. under power level of
40% taking care not to heat the contents longer than 2 min at a time to avoid
boiling off the reaction mixture. The contents were cooled and poured into ice
cold. water. Product was isolated and crystallised from ethanol.
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REACTION SCHEME
1,N-phenyl-3-(aryl)-5-(1’,N-phenyl-3’-p-nitorphenyl pyrazol-4’-yl)-pyrazoline
1,N-acetyl-3-(aryl)-5-(1',N-phenyl-3'-p-nitrophenyl pyrazol-4'-yl) pyrazoline
R=Aryl
R=Aryl
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Table 1:  IR spectral study of 1,N-phenyl-3-(p-anisyl)-5-(1’,N-phenyl-3’-p-
     nitorphenyl pyrazol-4’-yl)-pyrazoline (AS-2a)
N N
NO 2
N
N
R
Alkane
(Methyl)
Aromatic
Pyrazole
moiety
Ether
Pyrazoline
Frequency in cm-1
Observed Reported
2975 - 2920
2880 - 2850
1470 - 1435
1385 - 1350
1585 - 1480
1125 - 1090
1070-1000
845 - 810
1650 - 1590
1350 - 1200
1275-1200
1075- 1020
1650-1590
1585-1480
698-680
Type  Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-Cstr.(asym).
C-O-C(sym.)
C=N  str.
2922
2851
1415
1340
1502
1110
1000
838
1596
1299
1257
1033
1596
1502
691C-H def.
C=C
 
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmAS-3a
 507.2
 546.8
 607.5
 653.8
 691.4
 719.4
 761.8
 838.0
 960.5
1000.0
1033.8
1110.0
1174.6
1233.4
1256.5
1299.0
1340.4
1415.7
1502.4
1596.9
2851.6
2922.0
3310.6
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Table 2:  IR spectral study of 1,N-acetyl-3-(p-anisyl)-5-(1',N-phenyl-3'-p-
     nitrophenyl pyrazol-4'-yl) pyrazoline (AS-4a)
N N
NO2
N
N
R
O
CH3
Alkane
(Methyl)
Aromatic
Pyrazole
moiety
Ether
Pyrazoline
Frequency in cm-1
Observed Reported
2975 - 2950
2880 - 2860
1470 - 1435
1385 - 1350
3130 - 3030
1585 - 1480
1125 - 1090
845 - 810
1650 - 1590
1350 - 1200
1275-1200
1075- 1020
1650-1590
698-680
1585-1480
Type  Vibration  mode
C-H str.(asym.)
C-H str.(sym.)
C-H def.(asym.)
C-H def.(sym.)
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
C=N  str.
C-N str.
C-O-C str.(asym).
C-O-C (sym.)
C=N  str.
2922
2852
1448
1360
3093
1559
1067
838
1596
1328
1217
1038
1596
691
1502
C-H def.
C=C
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmap p-ch3 cry 23/5/5
 510.1
 542.9
 602.7 641.3
 687.6
 732.9
 756.0
 819.7
 838.0
 866.9
 962.4
1038.6
1067.5
1156.2
1217.0
1328.9
1360.7
1448.4
1507.3
1523.7
1559.3
1596.9
1661.6
2852.5
2922.9
3093.6
3310.6
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Table 3:  1H NMR spectra of 1,N-phenyl-3-(p-anisyl)-5-(1’,N-phenyl-3’-p-
     nitorphenyl pyrazol-4’-yl)-pyrazoline (AS-2a)
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N
N
NO2
N
N
OCH3
b
c
c'
b'
x
d e
e'd'
h
i
f'
f
g
g'
a
jml
k
l' m'
 Signal Signal Position Relative No.
Multiplicity Inference
J
No. (d ppm) of Protons         In Hz
1. 3.16-3.23 1H d. doublet CHh -
2. 3.76-3.82 1H d. doublet CHi -
3. 3.83 3H singlet Ar-OCH3 -
4. 5.39-5.45 1H d. doublet CHj -
5. 6.77-6.82 1H triplet Ar-Ha -
6. 6.89-6.92 2H doublet Ar-Hgg’ 6.96
7. 7.06-7.09 2H doublet Ar-Hdd' 8.7
8. 7.16-7.23 5H multiplet Ar-Hbb'+Hii’+Hk -
9. 7.35-7.41 2H triplet Ar-Hee' -
10. 7.62-7.70 4H triplet Ar-Hmm'+Hcc' -
11. 7.75-7.83 3H quartet Ar-Hff'+CHx -
1H NMR spectral data of 1,N-phenyl-3-(p-anisyl)-5-(1’,N-phenyl-3’-p-
nitorphenyl pyrazol-4’-yl)-pyrazoline (AS-2a)
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Table 4:  1HNMR spectra of  1,N-acetyl-3-(p-anisyl)-5-(1',N-phenyl-3'-p-
     nitrophenyl pyrazol-4'-yl) pyrazoline (AS-4a)
148
1H NMR  spectral data of 1,N-acetyl-3-(p-anisyl)-5-(1',N-phenyl-3'-p-nitrophenyl
pyrazol-4'-yl) pyrazoline (AS-4a)
N
N
NO2
N
N
O
CH3
OCH3
cb
a
b' c'
x
d
e
e'
d'
j
f g
g'f'
h
i
 Signal Signal Position Relative No. Multiplicity Inference J
No. (d ppm) of Protons         In Hz
1. 2.07 3H singlet COCH
3
-
2. 3.09-3.14 1H d. doublet CHh -
3. 3.61-3.71 1H d. doublet CHi -
4. 3.84 3H singlet Ar-OCH
3
-
5. 5.74-5.77 1H d. doublet CHj -
6. 6.90-6.93 2H doublet Ar-Hgg' Jgf=8.7
7. 7.09-7.15 2H triplet Ar-Hdd' -
8. 7.39-7.44 2H triplet Ar-Hbb' -
9. 7.59-7.62 2H doublet Ar-Hee' Jef=8.7
10. 7.68-7.71 2H doublet Ar-Hff' Jfg=7.9
11. 7.73-7.78 3H multiplet Ar-Hcc'+Ha -
12. 7.83 1H singlet CHx -
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RESULTS AND DISCUSSION
The physical constants of all the synthesized compounds by different techniques
are given in Table 7 and 8. The reaction time and yield of different synthesized
compounds by using microwave, ultrasonic waves and conventional techniques are
reported in Table 9. It is observed that using microwave and ultrasonic waves, the
reaction time is reduced considerably whereas % yield increased markedly.
        Further, the amount of catalyst required in these techniques is very less in
comparision to conventional method.
Thus, microwave and ultrasonics proved to be better technique than conventional
method.
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Code Yield % Reaction Time  
  
MW           US        Con. 
MW 
min 
US 
hrs 
Con. 
hrs 
AS-2a 77 66 61 6 1.45 10 
AS-2b 79 63 59 8 1.45 10 
AS-2c 75 66 65 7 1.45 10 
AS-2d 78 66 63 6 1.45 10 
AS-2e 86 67 67 6 1.30 10 
AS-2f 86 61 61 7 2.00 9 
AS-2g 84 63 62 8 2.00 9 
AS-2h 74 69 61 8 2.00 10 
AS-2i 72 68 61 6 2.00 10 
AS-2j 79 71 60 7 1.45 9 
AS-4a 68 69 59 6 1.45 10 
AS-4b 67 60 54 6 1.45 10 
AS-4c 73 54 59 6 1.45 10 
AS-4d 73 64 63 6 1.45 10 
AS-4e 73 62 54 7 2.00 10 
AS-4f 78 68 63 7 1.45 10 
AS-4g 79 61 60 6 1.30 10 
AS-4h 81 63 54 6 1.45 10 
AS-4i 67 69 66 6 1.45 10 
AS-4j 67 60 63 6 1.45 10 
     Table 9:  Comparision of  % Yield and Reaction time of compounds
                      synthesised by MW, US and Con. methods
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    GENERAL INTRODUCTION
Much advancement have been made in the field of science and technology
which helped people in leading a sophisticated yet luxurious life.
Several physico chemical parameters are available in the list and few of them
are of much interest. It was well understood by the literature that physico chemical
properties such as acoustical properties, conductivity, density, refractive index etc.
have contributed advancement in the physical sciences and also in daily human life.
Drug macro-molecular interactions are an important phenomenon in physiological
media, such as blood, membranes and intra and extra cellular fluids. Thermodynamic
properties like partial molar volume and partial molar compressibility are the few
sensitive indicators for understanding molecular interactions.
Refractive index is a very useful method to determine the structure and identity
of unknown compounds. Thermal analysis is one the important tool for the study of
thermal transformation of materials.
The study of physicochemical properties of compounds in solutions give
complete understanding of the behavior of compounds in different solvents. Literature
survey shows that very little work has been reported for the study of physico chemical
studies such as thermal properties, refractive index, conductance and ultrasonic of the
Schiff bases.
Thus, in this part of the thesis we have tried to add something in this field of
science. Physicochemical properties of some Schiff bases derived from 1, 2, 4-triazole
have been reported. Various physicochemical properties such as refractive index,
heat of solution, conductance, thermal properties and acoustical properties for Schiff
bases were determined in different solvents.
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INTRODUCTION
Ultrasonics is the study of high frequency sound waves, usually in excess of
20 KHz (20,000 Cycles per sec). Around 1880(1-3), Curies discovered the Piezoelectric
effect, which established the basis of ultrasound for the present day generation. Most
modern ultrasonic devices rely on transducers (energy converters), which are
composed of piezoelectrical material. Ultrasonic technology is now a days employed
in a wide range of applications in medicine, biology, industry, material science,
agriculture, oceanography, sonochemistry   research etc. due to its non-destructive
nature (4-8). Further, it is one of the most rapid and realiable technique for the
characterization of materials.
In medicine, it is used mostly for diagnosis of cancer cells(9). Applications in
materials science include the determination of some properties of solids such as
compressibility, specific heat ratios, elasticity(10) etc. Ultrasound has also proved to be
very useful for both soldering and welding. It is reported to improve the quality of
homogenized milk. With the tracking of submarines, oceanographic applications
include mapping the counters of the sea bottom, discovering sunken ships and
searching for schools of fish.
More recently, a lots of interest has been generated on the use of ultrasound
radiation in synthetic organic chemistry, which includes decrease of reaction time,
increase of yield, lower reaction temperature, avoidance of phase transfer
catalysis etc (11-16).
Further, cleaning is the most common type of applications of ultrasonic, which
includes the removal of grease, dirt, rust and paint from metal, ceramic glass and
crystal surfaces. Another area where ultrasonic is now-a-days being used, is to obtain
the information about microstructures(17,18). It is reported that these ultrasonic waves
provide valuable information about the structure of solids(19,20). By ultrasonic velocity
measurements, the molecular interactions in pure liquids (21-24), aqueous solutions (25)
and liquid mixtures(26, 27) can also be studied. It provides a powerful, effective and reliable
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tool to investigate properties of polymers(28-35), carbohydrates(36-38), amino acids(39-42),
solution of simple salts(43,44)etc.. However, very little work has been done for solid organic
compounds   (45-49). In our laboratory, ultrasonic measurements for some Schiff bases in
different solvents have been done(50-53).
Thus, in the present chapter, sound velocity studies of some triazole derivatives
in dimethylformamide (DMF) and tetrahydrofuran(THF) solution were done at 308.15
K with a view to understand the molecular interactions in these solutions.
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EXPERIMENTAL
Choice of Solvents:
Tetrahydrofuran (THF) and dimethylformamide (DMF) have been chosen as
solvents in the present work. These two solvents are of industrial interest because of
their wide use as solvents and solubilizing agents. THF is widely used in pharmaceutical
and cosmetic industries.
The densities, viscosities and ultrasonic velocities of solvents and solutions of
different concentration were measured at 308.15 K by using pyknometer, an Ubbelohde
suspended level viscometer and single frequency ultrasonic interferometer operating
at 2 MHz, with the uncertainties of 0.0001 g/cm3, + 0.06 % and 0.01% respectively.
Density measurements:
              The weight of distilled water, pure solvents and solutions of Schiff bases were
measured by using pyknometer. The densities were evaluated by using following
equation:
r (g/cm3) = [(wt. of solvent or solution) / (wt. of water)] x [density of water]
                                                                                                           ..…..… (1.1)
Viscosity Measurements:
           To determine the viscosity of solution, Ubbelohde viscometer(54) was used, which
obeys Stoke’s low(55). The measured quantity of the distilled water / solvent / solution
was placed in the viscometer, which was suspended in a thermostat at 308.15 K. The
digital stopwatch, with an accuracy of + 0.01 sec was used to determine flow time of
solutions. Using the flow times (t) and known viscosity of standard water sample, the
viscosity of solvent and solutions were determined according to equation:
                                            h1 / h2 = t1r1 / t2r2                                                         …. ….(1.2)
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Sound velocity measurement:
                 Ultrasonic interferometer (Model No. F-81), Mittal Enterprise, New Delhi,
working at frequency (F) of 2 MHz was used to determine sound velocity.
                  The solvent / solution were filled in the measuring cell with quartz crystal and
then micrometer was fixed. The circulation of water from the thermostat at 308.15 K
was started and test solvent / solution in the cell is allowed to thermally equilibrate. The
micrometer was rotated very slowly so as to obtain a maximum or minimum of anode
current (n). A number of maximum reading of anode current were counted. The total
distance (d) travel by the micrometer for n=10, was read. The wave length (l) was
determined according to the equation (1.3).
                                             l = 2d / n ………. (1.3)
               The sound velocity (U) of solvent and solutions were calculated from the
wavelength and frequency (F) according to equation (1.4).
                                                U = l F ………. (1.4)
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  RESULTS AND DISCUSSION
         The density (r), viscosity (h) and sound velocity (U) of pure solvents and different
Schiff bases solutions in tetrahydrofuran (THF) and dimethylformamide (DMF) were
calculated at 308.15  K and are given in Table 1.1.
         From these measurements, various acoustical parameters like specific acoustical
impendence (Z), isentropic compressibility (ks), intermolecular free length (Lf), Rao’s
molar sound function (Rm), molar compressibility (W), Vander Waals constant (b),
relaxation strength (r), internal pressure (p), solvation number (Sn) etc., were evaluated
using the following equations:
1. Specific acoustical impedance:
Specific acoustical impedance (Z) can be calculated as:
Z = Ur ………. (1.5)
2. Isentropic compressibility:
         Isentropic compressibility (ks) can be evaluated according to the following the
equation (56):
ks = 1/U
2r ………. (1.6)
3. Intermolecular free path length:
Jacobson (57) proposed an equation to calculate the intermolecular free path
length (Lf), which is given below:
Lf  = KJ ks
 1/2 ………. (1.7)
where KJ is Jacobson constant (=6.0816 x 10
4)
4. Molar compressibility:
Molar compressibility (W) can be calculated by the following equation (58):
W = (M/r) ks 
-1/7 ………. (1.8)
The apparent molecular weight (M) of the solution can be calculated according to
equation (1.10):
M = M1W1 + M2W2 ………. (1.10)
where W1 and W2 are weight fractions of solvent and solute, respectively. M1 and M2
are the molecular weights of the solvent and compounds respectively.
5. Rao’s molar sound function:
Rao’s molar sound function (Rm) can be evaluated by an equation given by
Bagchi et al (59):
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Rm = (M/r) U
1/3 ………. (1.9)
6. Van der Waals Constant:
Van der Waals constant (b) can be calculated as follows (60):
b = M/r {1- (RT/MU2)  Ö [1 +(MU2/ 3RT) – 1]}……. (1.11)
where R is the gas constant (=8.3143 JK-1 mol-1) and T is the absolute temperature.
7. Relaxation Strength:
The relaxation strength (r) can be calculated as follows (61):
r = 1- [U/U¥]
 2 ………. (1.12)
where U¥ = 1.6 x 10
5 cm/sec.
8. Relative Association (RA):
RA = r/r0 (U0/U)
1/3 ……….  (1.13)
where U, U0 and r, r0 are ultrasonic velocities and densities of solution and solvent
respectively.
9. Internal Pressure:
Suryanarayana and Kuppuswamy(62) gave the following equation for evaluating
internal pressure:
p = bRT [Kh/U] 1/2 r2/3/M7/6 ………. (1.14)
where b is the packing factor (= 2). K is a constant (=4.28 X 109).  The internal pressure
(p) depends on temperature, density, ultrasonic velocity and specific heat at constant
pressure.
10.    Free Volume:
   Free volume (63) can be calculated according to equation (1.15):
Vf  = [MU/Kh]
 3/2 ……….  (1.15)
Figure 1.1 and 1.2 shows the variation of ultrasound velocity (U) with
concentrations for all the Schiff bases in both the solvents, DMF and THF. The variations
of Intermolecular free length (Lf) with concentration of these bases are also shown in
Figure 1.3 and 1.4 for both the solvents. Comparision of these figures shows that
ultrasonic velocity (U) and intermolecular free length (Lf) are inversely related. Increase
in the Lf  causes velocity to decrease or vice versa.
The isentropic compressibility (ks) of the solutions in both the solvents is also
found to decrease with increase of concentration. This phenomenon can be explained
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by assuming that the solvated molecules are fully compressed by the electrical forces
of the ions(19). The compressibility of the solution is mainly due to the free solvent
molecules. Due to solute-solvent interaction in the system, compressibility of the solution
decreases with the increase in solute concentration. This is further confirmed by
decrease of relaxation strength (r) and increase in specific impedance (Z) values.
The increase in viscosity in both solvents also confirms the same. The association
between solute and solvent molecules is further confirmed by relative association (RA)
values, which are found to increase continuously with concentration for all the compounds
in both the solvents.
       In both DMF and  THF solutions, the Rao’s molar sound function (Rm), Vander
Waal’s constant (b) and molar compressibility (W) for all the solutions are observed to
increase linearly, which suggest that no complex or aggregate formation takes place
in these solutions.  Figure 1.5, 1.6 and 1.7 shows the linear  variation of Rm, b and W
with concentration in both DMF and THF solutions for HAS-1 to HAS-5 Schiff bases.
This is further supported by the values of correlation coefficient (g) which are given in
Table 1.4 along with the correlation  equations for some acoustical parameters.
The internal pressure (p) is the resultant of forces of attraction and repulsion
between the molecules in a solution.  Table 1.2 shows that in both THF and DMF
solutions, internal pressure decreases with concentration. The decrease in internal
pressure indicates the decrease in cohesive forces. Although decrease in
compressibility, internal molecular free length, relaxation strength and increase of
velocity, viscosity suggest predominance of solute-solvent interaction, the decrease in
internal pressure indicates the existence of other interactions also (solute-solute
interactions) in these solutions. This is further supported by free volume. The free volume
(Vf) of a solute molecule at a particular temperature and pressure depends on the
internal pressure of a liquid in which it is dissolved. The decrease in molecular
association causes an increase in free volume. Thus, free volume is an inverse function
of internal pressure.  Hence, increase in free volume causes internal pressure to
decrease or vice versa. However, Table 1.2 shows that although internal pressure
decreasing linearly, free volume varies irregularly for different Schiff bases in both
DMF and THF. This again confirms the existence of both solute-solute and solute-
solvent interaction in these systems.
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The apparent molar compressibility (FK) of the solutions was calculated by the following
equation:
FK = (?0ks- ?ks0) 1000/c?0+ks0M2/?0 ………. (1.18)
where ks0 is isentropic compressibility of pure solvent. These FK values were fitted with
Gucker’s relation(64):
FK = FK
o +SK ÖC ……….. (1.19)
It is found that the relation is applicable above 0.04M concentrations. From the plots of
FK verses ÖC, values of intercept (FK
o) and slope (SK) were calculated.
Further, apparent molar volumes FV of the solutions were calculated by the following
equation:
Fv  = M/?-[1000(?-?0)/?c] ………. (1.20)
and were fitted in the relation:
FV = FV
o
 +Sv  ÖC ………. (1.21)
      From the plot of FV verses ÖC, FV
o
 and Sv  values were calculated from the
intercept and slope respectively. S v  is the measure of solute-solvent interaction. These
values of FV
o and Sv , along with the Gucker’s constants FK
o and Sk are reported in
Table-1.3.
Table 1.3 shows that in DMF solutions, for all other Schiff bases solutions (except
HAS-1), f ok values are positive but less whereas Sk values are both positive and
negative. However, in THF solutions, for all Schiff bases, f 0k values are negative
whereas SK values are positive. The negative or less positive f
0
k values and positive
SK values indicate the existence of solute-solvent interactions or vice versa. Thus, in
DMF solutions, although solute-solvent interactions predominates, solute-solute
interactions also exist. Whereas, in THF solutions, solute-solvent interaction exists.
The predominance of any of these interactions is further confirmed by f oV and SV values.
The negative f oV and higher SV values indicate the predominance of solute-solvent
interactions in the system. Thus, in both DMF and THF solutions, solute-solvent
interactions exist. It is reported by Nikam and Hiray that the negative f oV and positive
SV suggest electrostrictive solvation of ions
(65,66).
Thus, both solute-solute and solute-solvent interactions exist in both DMF and
THF solutions. However, in THF, most of the parameters indicate the predominance of
168
solute-solvent interactions, internal pressure and free volume indicate some solute-
solute interactions also. In DMF, the two lone pair of electrons may interact differently
with different solute molecules. Thus, the dipole –dipole interactions between solute
and solvent molecules play an important role in DMF solutions due to which
predominance of type of interaction is much affected.
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Figure 1.1: Variation of ultrasonic velocity (U) with concentration in [A]  DMF
    and [B] THF at 308.15 K.
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Figure 1.2: Variation of ultrasonic velocity (U) with concentration in [A]  DMF
and [B] THF at 308.15 K.
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Figure 1.3: Variation of intermolecular free path length (Lf) with    concentration
in [A] DMF and [B] THF at 308.15 K.
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 Figure 1.4: Variation of intermolecular free path length (L f) with   concentration
 in [A] DMF and [B] THF at 308.15 K.
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Figure 1.5: Variation of Rao’s molar constant (Rm) with concentration in [A]
 DMF and [B] THF at 308.15 K.
[A]
4
4.2
4.4
4.6
4.8
0 0.02 0.04 0.06 0.08 0.1 0.12
Concentration (M)
R
m
HAS-1
HAS-2
HAS-3
HAS-4
HAS-5
[B]
4
4.2
4.4
4.6
4.8
0 0.02 0.04 0.06 0.08 0.1 0.12
Concentration (M)
R
m
HAS-1
HAS-2
HAS-3
HAS-4
HAS-5
174
Figure 1.6:Variation of Vander Walls constant (b) with concentration in [A] DMF
and [B] THF at 308.15 K.
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Figure 1.7: Variation of Molar compressibility (W) with concentration in [A] DMF
and [B] THF at 308.15 K.
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Figure 1.8:  Variation of Free volume (V f) with concentration in  [A] DMF and [B]
THF at 308.15 K.
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Figure 1.9:  Variation of Free volume (V f) with concentration in  [A] DMF and [B]
THF at 308.15 K.
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Table 1.3   Various constants of Bachem’s and Gucker’s equation
 
 DMF 
  
  
F oK x 108 
 
SK x108 
 
F oV 
 
SV 
HAS-1. -1.02 0.85 -462.53 1133.1 
HAS-2. 9.8 -40.00 -111.95 158.8 
HAS-3. 5.8 -19.59 -365.14 862.0 
HAS-4. 9.1 -10.00 -481.99 1207.8 
HAS-5. 10.6 32.13 -244.74 463.7 
HAS-6 7.00 26.67 -285.00 1764.7 
HAS-7 9.00 18.57 -177.00 1184.2 
HAS-8 7.00 17.15 -190.00 1425.0 
HAS-9 5.00 10.71 85.00 3250.0 
HAS-10 13.00 32.50 -45.00 117.6 
 
 
THF   
HAS-1. -3.7 5.48 -171.33 574.6 
HAS-2. -19.8 30.00 -153.24 1122.5 
HAS-3. -5.8 12.96 -20.00 722.2 
HAS-4. -4.95 11.75 -21.77 812.6 
HAS-5. -8.55 14.62 -60.42 307.7 
HAS-6 -11.3 25.19 -132.00 300.0 
HAS-7 -9.5 30.30 -158.00 1125.0 
HAS-8 -1.7 3.24 3.01 600.1 
HAS-9 -9.0 22.50 -76.00 312.5 
HAS-10 -3.3 7.37 -146.11 1400.0 
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Table 1.4: The correlation coefficients (g) and correlation equations between
                    some acoustical parameters and concentrations (C) of Schiff base
                    in DMF and THF at 308.15 K.
Parameters   g Correlation equation
DMF
HAS-1
? (poise) 0.9912 ?-10.741C=7.7255
ks (cm
2.dyn-1) 0.9218 ks+2.7661C=5.1434
Lf (A
O) 0.9237 Lf+0.1191C=0.4300
Z (gm.cm-2s-1) 0.9448 Z- 0.4624C=1.3511
W (cm-1.dyn-1) 0.9997 W- 2.6112C=2.2905
b (cm3.mol-1) 0.9999 b-79.854C=73.182
Rm (cm
-8/3.sec-1/3) 0.9996 Rm- 4.6058C=4.0793
r 0.9022 r+ 0.3553C=0.1916
RA 0.8953 RA- 0.0501C=1.0103
HAS-2
? (poise) 0.9801 ?-8.7671C=7.3407
ks (cm
2.dyn-1) 0.9780 ks+1.4010C=5.3039
Lf (A
O) 0.9777 Lf+0.0595C=0.4429
Z ( gm.cm-2s-1) 0.9819 Z- 0.2647C=1.3271
W (cm-1.dyn-1) 0.9997 W- 2.7807C=2.2992
b (cm3.mol-1) 0.9876 b-84.8630C=73.676
Rm (cm
-8/3.sec-1/3) 0.9996 Rm- 4.8714C=4.0848
r 0.9333 r+ 0.1129C=0.2117
RA 0.9661 RA- 0.1046C=1.0091
Continue......
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Parameters   g Correlation equation
 DMF
HAS-3
? (poise) 0.8627 ?-11.013C = 7.8608
ks (cm
2.dyn-1) 0.9917 ks+ 2.050C = 5.1553
Lf (A
O) 0.9915 Lf+ 0.0876C = 0.4366
Z ( gm.cm-2s-1) 0.9963 Z- 0.357C   = 1.3489
W (cm-1.dyn-1) 0.9996 W- 2.6197C = 2.298
b (cm3.mol-1) 0.9997 b- 81.567C = 73.25
Rm (cm
-8/3.sec-1/3) 0.9994 Rm- 4.6102C = 4.0824
r 0.9688 r+ 0.2392C = 0.1926
RA 0.8705 RA- 0.0677C = 1.0095
HAS-4
? (poise) 0.9574 ?-14.257C = 7.8698
ks (cm
2.dyn-1) 0.9194 ks+ 1.6067C = 5.1432
Lf (A
O) 0.9210 Lf+ 0.0691C = 0.4362
Z (gm.cm-2s-1) 0.9420 Z- 0.3063C = 1.3506
W (cm-1.dyn-1) 0.9999 W- 3.0988C = 2.2991
b (cm3.mol-1) 0.9998 b- 98.082C = 73.262
Rm(cm
-8/3.sec-1/3) 0.9998 Rm- 5.4368C = 4.0847
r 0.8663 r+ 0.1501C = 0.1906
RA 0.9675 RA- 0.1036C = 1.0091
      ........Continue
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Parameters   g Correlation equation
 DMF
HAS-5
?(poise) 0.9913 ?-11.033C = 7.4204
ks (cm
2.dyn-1) 0.9985 ks+ 1.6931C = 5.2756
Lf(A
O) 0.9986 Lf+ 0.0714C = 0.4417
Z( gm.cm-2s-1) 0.9953 Z- .3141C = 1.332
W(cm-1.dyn-1) 0.9996 W- 2.837C = 2.2961
b(cm3.mol-1) 0.9995 b- 89.753C = 73.399
Rm(cm
-8/3.sec-1/3) 0.9994 Rm- 4.970C = 4.0782
r 0.9933 r+ 0.1507C = 0.2092
RA 0.9533 RA- 0.1091C = 1.0108
HAS-6
?(poise) 0.9537 ?-10.296C = 7.8577
ks (cm
2.dyn-1) 0.9957 ks+ 2.186C = 5.1661
Lf(A
O) 0.9986 Lf+ 0.0714C = 0.4417
Z( gm.cm-2s-1) 0.9952 Z- 0.3838C = 1.348
W(cm-1.dyn-1) 0.9999 W- 3.0864C = 2.2958
b(cm3.mol-1) 0.9999 b- 96.508C = 73.198
Rm(cm
-8/3.sec-1/3) 0.9999 Rm- 5.4298C = 4.0777
r 0.9936 r+ 0.250C = 0.195
RA 0.9481 RA- 0.0773C = 1.0109
       .......Continue
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Parameters   g Correlation equation
 DMF
HAS-7
? (poise) 0.9820 ?-10.6600C = 7.347
ks (cm
2.dyn-1) 0.9682 ks+ 1.8965C = 5.3408
Lf (A
O) 0.9665 Lf+ 0.08C = 0.4445
Z ( gm.cm-2s-1) 0.9824 Z- 0.3325C = 1.3230
W (cm-1.dyn-1) 0.9997 W- 3.0931C = 2.2948
b (cm3.mol-1) 0.9998 b- 97.927C = 73.457
Rm (cm
-8/3.sec-1/3) 0.9996 Rm- 5.4294C = 4.0756
r 0.9292 r+ 0.1795C = 0.2179
RA 0.9708 RA- 0.0968C = 1.0115
HAS-8
? (poise) 0.9395 ?-11.737C = 7.3167
ks (cm
2.dyn-1) 0.9967 ks+ 1.6981C = 5.2701
Lf (A
O) 0.9957 Lf+ 0.0712C = 0.4415
Z ( gm.cm-2s-1) 0.9979 Z- 0.2959C = 1.3326
W (cm-1.dyn-1) 1.0000 W- 2.9182C = 2.2967
b (cm3.mol-1) 1.0000 b- 92.38C = 73.399
Rm (cm
-8/3.sec-1/3) 1.0000 Rm- 5.1327C = 4.0796
r 0.9950 r+ 0.1722C = 0.2081
RA 0.9935 RA- 0.9935C = 1.0103
       ........Continue
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Parameters   g Correlation equation
DMF
HAS-9
? (poise) 0.9994 ?-14.603C = 7.3079
ks (cm
2.dyn-1) 0.9565 ks+ 2.6341C = 5.2885
Lf (A
O) 0.9578 Lf+ 0.1116C = 0.4423
Z ( gm.cm-2s-1) 0.9778 Z- 0.4445C = 1.3294
W (cm-1.dyn-1) 0.9995 W- 2.5381C = 2.2982
b (cm3.mol-1) 0.9998 b- 78.143C = 73.484
Rm (cm
-8/3.sec-1/3) 0.9993 Rm- 4.4523C = 4.0827
r 0.9211 r+ 0.2936C = 0.2102
RA 0.9296 RA- 0.0868C = 1.0096
HAS-10
? (poise) 0.9687 ?-6.6302C = 7.3046
ks (cm
2.dyn-1) 0.9912 ks+ 1.8832C = 5.4174
Lf (A
O) 0.9903 Lf+ 0.779C = 0.4476
Z ( gm.cm-2s-1) 0.9917 Z- 0.3138C = 1.3126
W (cm-1.dyn-1) 0.9998 W- 2.2617C = 2.2936
b (cm3.mol-1) 0.9997 b- 70.912C = 73.543
Rm (cm
-8/3.sec-1/3) 0.9998 Rm- 3.966C = 4.0731
r 0.9869 r+ 0.1844C = 0.2277
RA 0.9815 RA- 0.0814C = 1.0018
        ........Continue
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Parameters   g Correlation equation
THF
HAS-1
? (poise) 0.9981 ?-6.9717C=4.3878
ks (cm
2.dyn-1) 0.9893 ks+3.3819C=7.7402
Lf (A
O) 0.9901 Lf+0.1180C=0.5351
Z ( gm.cm-2s-1) 0.9932 Z- 0.3289C=1.0609
W (cm-1.dyn-1) 0.9999 W- 2.7245C=2.3038
b (cm3.mol-1) 0.9999 b-89.118C=77.124
Rm (cm
-8/3.sec-1/3) 0.9999 Rm- 4.7766C=4.1035
r 0.9790 r+0.1674C=0.4211
RA 0.9816 RA-0.1161C=0.9996
HAS-2
? (poise) 0.8597 U-0.2665C=1.2237
ks (cm
2.dyn-1) 0.9960 ?-4.9224C=4.3795
Lf (A
O) 0.9607 ks+3.5898C=7.6005
Z ( gm.cm-2s-1) 0.9601 Lf+0.1270C=0.5302
W (cm-1.dyn-1) 0.9769 Z- 0.3385C=1.0711
b (cm3.mol-1) 0.9997 W- 3.1108C=2.3077
Rm (cm
-8/3.sec-1/3) 0.9999 b-101.7300C=77.0920
r 0.9996 Rm- 5.4879C=4.1116
RA 0.9319 r+0.2074C=0.4109
        ........Continue
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Parameters   g Correlation equation
THF
HAS-3
? (poise) 0.9834 ?-4.3479C = 4.4839
ks (cm
2.dyn-1) 0.9772 ks+ 2.6349C = 7.6707
Lf (A
O) 0.9781 Lf+ 0.093C = 0.5327
Z (gm.cm-2s-1) 0.9823 Z-0.2546C = 1.0655
W (cm-1.dyn-1) 0.9997 W- 2.8517C = 2.308
b (cm3.mol-1) 0.9997 b- 94.442C = 77.181
Rm (cm
-8/3.sec-1/3) 0.9997 Rm- 5.0264C = 4.1122
r 0.9627 r+ 0.1337C = 0.4153
RA 0.9492 RA- 0.0848C = 0.9974
HAS-4
? (poise) 0.9927 ?-7.2169C = 4.3898
ks (cm
2.dyn-1) 0.9908 ks+ 3.3276C = 7.7353
Lf (A
O) 0.9919 Lf+ 0.1162C = 0.5349
Z (gm.cm-2s-1) 0.9903 Z- 0.3227C = 1.0604
W (cm-1.dyn-1) 0.9995 W- 3.390C = 2.3083
b (cm3.mol-1) 0.9994 b- 111.98C = 77.276
Rm (cm
-8/3.sec-1/3) 0.9994 Rm- 5.8322C = 4.1227
r 0.9847 r+ 0.166C = 0.4197
RA 0.9616 RA- 0.1131C = 0.9976
       .......Continue
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Parameters   g Correlation equation
THF
HAS-5
? (poise) 0.9962 ?-4.8687C = 4.3766
ks (cm
2.dyn-1) 0.9882 ks+ 2.9557C = 7.6673
Lf (A
O) 0.9883 Lf+ 0.1037C = 0.5325
Z (gm.cm-2s-1) 0.9925 Z- 0.2909C = 1.0654
W (cm-1.dyn-1) 0.9999 W- 3.1484C = 2.3098
b (cm3.mol-1) 1.0000 b- 104.12C = 77.241
Rm (cm
-8/3.sec-1/3) 0.9999 Rm- 5.5402C = 4.1159
r 0.9811 r+ 0.1468C = 0.4148
RA 0.9976 RA- 0.1047C = 0.9966
HAS-6
? (poise) 0.9681 ?-7.1306C = 4.4351
ks (cm
2.dyn-1) 0.9977 ks+ 4.6144C = 7.6286
Lf (A
O) 0.9830 Lf+ 0.134C = 0.5304
Z (gm.cm-2s-1) 0.9859 Z- 0.3711C = 1.0696
W (cm-1.dyn-1) 1.0000 W- 3.6916C = 2.3128
b (cm3.mol-1) 1.0000 b- 121.32C = 77.276
Rm (cm
-8/3.sec-1/3) 1.0000 Rm- 6.4991C = 4.1221
r 0.9787 r+ 0.2033C = 0.4102
RA 0.9911 RA- 0.1151C = 0.9953
        ........Continue
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Parameters   g Correlation equation
THF
HAS-7
? (poise) 0.9849 ?-3.424C = 4.4193
ks (cm
2.dyn-1) 0.9754 ks+ 2.4817C = 7.7041
Lf (A
O) 0.9767 Lf+ 0.0865C = 05338
Z (gm.cm-2s-1) 0.9813 Z- 0.2282C = 1.0643
W (cm-1.dyn-1) 0.9999 W- 3.5022C = 2.3016
b (cm3.mol-1) 0.9999 b- 117.01C = 77.005
Rm (cm
-8/3.sec-1/3) 0.9998 Rm- 6.1975C = 4.0991
r 0.9592 r+ 0.1357C = 0.4191
RA 0.8926 RA- 0.0758C = 0.9991
HAS-8
? (poise) 0.9905 ?-3.6799C = 4.3782
ks (cm
2.dyn-1) 0.9786 ks+ 2.7452C = 7.7502
Lf (A
O) 0.9802 Lf+ 0.0959C = 0.5354
Z (gm.cm-2s-1) 0.9825 Z- 0.2681C = 1.0592
W (cm-1.dyn-1) 0.9997 W- 2.8516C = 2.3071
b (cm3.mol-1) 0.9996 b- 104.91C = 77.278
Rm (cm
-8/3.sec-1/3) 0.9995 Rm- 5.5524C = 4.1123
r 0.9620 r+ 0.1293C = 0.4206
RA 0.9433 RA- 0.1015C = 0.9975
        ........Continue
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Parameters   g Correlation equation
THF
HAS-9
? (poise) 0.9709 ?-5.0902C = 4.4277
ks (cm
2.dyn-1) 0.9821 ks+ 2.9736C = 7.6852
Lf (A
O) 0.9838 Lf+ 0.105C = 0.5332
Z ( gm.cm-2s-1) 0.9866 Z- 0.2747C = 1.0644
W (cm-1.dyn-1) 0.9999 W- 3.1568C = 2.308
b (cm3.mol-1) 0.9999 b- 93.994C = 77.171
Rm (cm
-8/3.sec-1/3) 0.9998 Rm- 5.0368C = 4.1106
r 0.9727 r+ 0.1662C = 0.4165
RA 0.9421 RA- 0.0670C = 0.9977
HAS-10
? (poise) 0.9934 ?-4.4341C = 4.4035
ks (cm
2.dyn-1) 0.9881 ks+ 2.499C = 7.7378
Lf (A
O) 0.9887 Lf+ 0.087C = 0.5349
Z ( gm.cm-2s-1) 0.9893 Z- 0.2395C = 1.0610
W (cm-1.dyn-1) 0.9999 W- 2.4877C = 2.3038
b (cm3.mol-1) 0.9998 b- 82.236C = 77.12
Rm (cm
-8/3.sec-1/3) 0.9998 Rm- 4.3768C = 4.1037
r 0.9860 r+ 0.1238C = 0.4207
RA 0.9742 RA- 0.0817C = 0.9994
       ........Continue
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    INTRODUCTION
One of the common use of the refractive index is to compare the value obtained
with the values listed in the literature. This comparison is used to confirm the identity of
the compound and assess its substances(1). The concentration of a solute in a solution
is probably the most popular use of refractometry for example, determining the
percentage of sugar in fruits, juices and syrups(2), the percentage of alcohol in beer or
wine, the salinity of water, and concentration of antifreeze in radiator fluid. Further,
refractive indexes along with density, molecular mass and specific volume are also
useful in the evaluation of various thermodynamic properties of chemical materials.
Van Nes and Van Westen gave the method for the analysis of petroleum fraction using
refractometry(3). Recently, refractive index measurements have been used to determine
complex refractive index(4) and film thickness(5).
Much work has been done in liquid mixtures (6-18) but scanty work has been
reported for the solutions (19-26), which includes solutions of organic, inorganic
and polymeric materials. However, very little work has been reported on Schiff
bases in solutions (27-30).
In this chapter, the density and refractive index of all triazole Schiff bases
have determined in dimethylformamide (DMF) and tetrahydrofuran (THF) solutions
at 308.15 K.
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EXPERIMENTAL
The solvents DMF and THF were of LR grade and are fractionally distilled by
the reported method(31). All the Schiff bases were recrystalized from methanol. For
each Schiff base, a series of solutions of different concentrations were prepared in
both the solvents. The density and refractive index of solutions are measured by using
Pyknometer and Abbe Refrectometer respectively at 308.15 K. The results are given
in Tables 2.1 and 2.2.
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RESULTS AND DISCUSSION
The density of solution (?12) is related to densities of the solvent, solute and
their weight fractions g1 and g2, according to the equation:
                                  1/?12 = g1/?1 + g2/?2                                      ………. (2.1)
where r12 is density of solution and r1 and r2 are the densities of the solvent and solute
respectively. Tables 2.1 and 2.2 shows the experimental values of densities and
refractive index for all the Schiff bases in different solutions of DMF and THF.
The density of these Schiff bases was determined from the slope of the plot of
1/ g1?12 verses g2/g1. Figure 2.1 shows the plots of 1/?12g1 verses g2/g1 for HAS-1 in
DMF and THF respectively. The inverse of slope gives ?2 i.e., the density of solute.
The density of all the Schiff bases calculated from such plots are given in Table 2.3.
          Further, from the knowledge of structural aspects, the density of a compound
can be determined by following equation (32).
? = KM / NASDVi       ………. (2.2)
where r is the density of the compound, K is packing fraction (0.599), M is the molecular
weight of the compound, NA is the Avogadro’s number and DVi is the volume increment
of the atoms and atomic groups present in the compound. DVi for some of the atoms
and group of atoms are reported in Table 2.5. The densities calculated from equation
(2.2) are given in Table 2.3.
It is evident from Table 2.3 that the evaluated values of densities for all the
compounds from equation 2.2 differs from those calculated by refractive index
measurements in DMF and THF. However, in some cases, deviation is less in one of
the solvent, THF. This suggests that the presence of molecular interactions in different
solvents affect the density of solute. Usually intermolecular interactions does not affect
the density but due to the presence of different substituted groups in solutes, interactions
differ in different solvents which may cause change in volume thereby affecting the
density of solute in particular solvent.  This is further confirmed by ultrasonic studies
explained in chapter-1.
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The molar refraction of pure liquid and solutions can be determined according
to Lorentz and Lorentz (33) equations (2.3) and (2.4) respectively.
For pure liquid:
                         (MRD) = [(n2 – 1) / (n2 + 2)]. M/?                                   ……. (2.3)
where n, M and r are refractive index, molecular weight and density of pure liquid
respectively.
For solutions:
(MRD) 12= [(n
2
12 – 1) / (n
2
12 + 2)]. (X1M1 + X2M2) / ?12                 ……. (2.4)
       where n12 and r12 are refractive index and density of the solution respectively. X1
and X2 are the mole fractions and M1 and M2 are the molecular weights of the solvent
and solute respectively.
         The plots of (MRD)12 verses concentration for all the Schiff bases in DMF and
THF are given in Figures 2.2 and 2.3 respectively. It is evident from the figures that
(MRD) 12 increases with increase in concentration. From the values of the molar
refraction of solution and pure solvent, molar refraction of solid compounds were
determined by the following equation:
                (MRD) 12= X1 (MRD) 1+ X2 (MRD) 2                                        ……….(2.5)
         From the density and molar refraction data, the refractive index of each Schiff
bases was calculated from equation (2.3). The molar refraction and refractive index of
all the Schiff bases are reported in Table 2.4.
It is evident from Table 2.4 that both (MRD)2 and refractive index of compounds
are different in each solvent. This again proves that in different solvents, intermolecular
interactions are different, which affect these parameters. In some solvents, aggregation
or hydrogen bonding takes place whereas in others, breakage of bonds takes place.
As refractive index and molar refraction depends not only upon atomic refractions but
also upon single, double or triple bonds(28), these parameters are affected by the type
of interactions taking place in solution. However, it is reported that bond refraction is
more effective than atomic refraction (34-36). Further, bond polarity also causes change
in molar refraction(37). This again suggests the effect of solvent on refractive index and
molar refraction of the solute.
205
Table 2.1: The density (r12) and refractive index (n) of Schiff bases in 
dimethyl formamide at 308.15 K.  
 
Conc. (M) r12 g1 g2 n 
HAS-1 
0.00 - - - 1.411 
0.01 0.9398 0.9966 0.0034 1.414 
0.02 0.9416 0.9931 0.0069 1.415 
0.04 0.9444 0.9863 0.0137 1.417 
0.06 0.9464 0.9795 0.0205 1.418 
0.08 0.9478 0.9727 0.0273 1.419 
0.10 0.9507 0.9660 0.0340 1.422 
HAS-2 
0.01 0.9359 0.9936 0.0024 1.412 
0.02 0.9364 0.9931 0.0069 1.413 
0.04 0.9387 0.9863 0.0137 1.415 
0.06 0.9404 0.9795 0.0205 1.416 
0.08 0.9445 0.9727 0.0273 1.417 
0.10 0.9461 0.9643 0.0357 1.418 
HAS-3 
0.01 0.9393 0.9997 0.0003 1.415 
0.02 0.9402 0.9937 0.0063 1.416 
0.04 0.9428 0.9862 0.0138 1.419 
0.06 0.9448 0.9793 0.0209 1.420 
0.08 0.9480 0.9725 0.0275 1.422 
 0.9484 0.9657 0.0343 1.423 
HAS-4 
0.01 0.9390 0.9962 0.0038 1.414 
0.02 0.9402 0.9925 0.0075 1.415 
0.04 0.9446 0.9850 0.0150 1.417 
0.06 0.9462 0.9776 0.0224 1.418 
0.08 0.9486 0.9702 0.0298 1.420 
0.10 0.9500 0.9628 0.0372 1.421 
HAS-5 
0.01 0.9378 0.9964 0.0036 1.412 
0.02 0.9385 0.9927 0.0073 1.414 
0.04 0.9411 0.9855 0.0145 1.415 
0.06 0.9450 0.9783 0.0217 1.417 
0.08 0.9456 0.9711 0.0289 1.418 
0.10 0.9497 0.9641 0.0359 1.419 
        Continue.....
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Conc. (M) r12 g1 g2 n 
HAS-6 
0.01 0.9397 0.9963 0.0037 1.413 
0.02 0.9417 0.9926 0.0074 1.414 
0.04 0.9436 0.9852 0.0148 1.416 
0.06 0.9471 0.9778 0.0222 1.418 
0.08 0.9489 0.9705 0.0295 1.419 
0.10 0.9505 0.9632 0.0368 1.420 
HAS-7 
0.01 0.9359 0.9962 0.0037 1.411 
0.02 0.9381 0.9925 0.0075 1.412 
0.04 0.9404 0.9850 0.0150 1.413 
0.06 0.9425 0.9776 0.0224 1.415 
0.08 0.9446 0.9702 0.0298 1.417 
0.10 0.9480 0.9628 0.0372 1.418 
HAS-8 
0.01 0.9368 0.9664 0.0036 1.413 
0.02 0.9381 0.9927 0.0073 1.414 
0.04 0.9405 0.9855 0.0145 1.415 
0.06 0.9423 0.9783 0.0217 1.416 
0.08 0.9443 0.9711 0.0289 1.419 
0.10 0.9465 0.9639 0.0360 1.420 
HAS-9 
0.01 0.9364 0.9930 0.0070 1.412 
0.02 0.9376 0.9931 0.0069 1.414 
0.04 0.9400 0.9862 0.0138 1.416 
0.06 0.9435 0.9794 0.0206 1.417 
0.08 0.9463 0.9727 0.0273 1.418 
0.10 0.9484 0.9659 0.0341 1.419 
HAS-10 
0.01 0.9345 0.9962 0.0038 1.412 
0.02 0.9360 0.9925 0.0075 1.413 
0.04 0.9377 0.9850 0.0150 1.414 
0.06 0.9405 0.9776 0.0224 1.415 
0.08 0.9418 0.9702 0.0298 1.417 
0.10 0.9450 0.9628 0.0372 1.418 
 
           .....Continue
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     Table 2.2:     The density (r12) and refractive index (n) of Schiff bases  
             in tetrahydrofuran at 308.15 K. 
 
 
Conc. (M) r12 g1 g2 n 
HAS-1 
0.00 - - - 1.385 
0.01 0.8727 0.9963 0.0037 1.387 
0.02 0.8740 0.9926 0.0074 1.388 
0.04 0.8775 0.9853 0.0147 1.391 
0.06 0.8807 0.9780 0.0220 1.393 
0.08 0.8829 0.9707 0.0293 1.394 
0.10 0.8823 0.9635 0.0365 1.396 
HAS-2 
0.01 0.8732 0.9961 0.0039 1.391 
0.02 0.8746 0.9923 0.0077 1.392 
0.04 0.8769 0.9846 0.0154 1.393 
0.06 0.8801 0.9770 0.0220 1.394 
0.08 0.8823 0.9694 0.0306 1.395 
0.10 0.8837 0.9618 0.0382 1.396 
HAS-3 
0.01 0.8719 0.9963 0.0037 1.391 
0.02 0.8731 0.9926 0.0075 1.392 
0.04 0.8749 0.9851 0.0149 1.393 
0.06 0.8776 0.9778 0.0222 1.394 
0.08 0.8805 0.9705 0.0295 1.395 
0.10 0.8809 0.9631 0.0369 1.396 
HAS-4 
0.01 0.8721 0.9960 0.0040 1.386 
0.02 0.8728 0.9919 0.0081 1.387 
0.04 0.8750 0.9839 0.0161 1.390 
0.06 0.8784 0.9759 0.0241 1.391 
0.08 0.8804 0.9679 0.0321 1.392 
0.10 0.8849 0.9601 0.0399 1.397 
HAS-5 
0.01 0.8714 0.9961 0.0039 1.388 
0.02 0.8733 0.9922 0.0078 1.389 
0.04 0.8755 0.9844 0.0156 1.390 
0.06 0.8782 0.9767 0.0233 1.392 
0.08 0.8808 0.9690 0.0310 1.394 
0.10 0.8830 0.9951 0.0049 1.396 
Continue.....
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Conc. (M) r12 g1 g2 n 
HAS-6 
0.01 0.8714 0.9960 0.0040 1.388 
0.02 0.8734 0.9920 0.0080 1.389 
0.04 0.8769 0.9840 0.0180 1.391 
0.06 0.8803 0.9761 0.0239 1.392 
0.08 0.8825 0.9683 0.0317 1.394 
0.10 0.8850 0.9604 0.0396 1.395 
HAS-7 
0.01 0.8735 0.9960 0.0040 1.385 
0.02 0.8738 0.9919 0.0081 1.386 
0.04 0.8767 0.9839 0.0161 1.387 
0.06 0.8767 0.9759 0.0241 1.389 
0.08 0.8790 0.9679 0.0321 1.394 
0.10 0.8810 0.9600 0.0400 1.395 
HAS-8 
0.01 0.8708 0.9961 0.0039 1.387 
0.02 0.8721 0.9922 0.0078 1.388 
0.04 0.8742 0.9844 0.0156 1.389 
0.06 0.8765 0.9767 0.0233 1.390 
0.08 0.8779 0.9689 0.0311 1.392 
0.10 0.8817 0.9613 0.0387 1.393 
HAS-9 
0.01 0.8716 0.9963 0.0037 1.388 
0.02 0.8727 0.9926 0.0074 1.390 
0.04 0.8753 0.9852 0.0148 1.391 
0.06 0.8777 0.9779 0.0221 1.392 
0.08 0.8788 0.9706 0.0294 1.394 
0.10 0.8805 0.9633 0.0367 1.395 
HAS-10 
0.01 0.8717 0.9965 0.0035 1.387 
0.02 0.8740 0.9925 0.0075 1.388 
0.04 0.8758 0.9860 0.0140 1.390 
0.06 0.8773 0.9790 0.0210 1.392 
0.08 0.8795 0.9720 0.0280 1.393 
0.10 0.8816 0.9651 0.0349 1.394 
 
        ......Continue
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Table 2.3: Experimental and calculated densities of Schiff bases in DMF 
and THF solutions at 308.15 K. 
 
 
 
     Compounds 
Density calculated from slope of Fig. 2.1 
in two Solvents 
 
Density gm/cm2 
Calculated from  
eqn. 2 
  
DMF 
 
THF 
 
 
HAS-1 1.4815 1.4999 1.2104 
HAS-2 1.4166 1.3421 1.2571 
HAS-3 1.1730 1.3399 1.3046 
HAS-4 1.2500 1.2812 1.3367 
HAS-5 1.3959 1.4318 1.3149 
HAS-6 1.3793 1.3669 1.3000 
HAS-7 1.4999 1.1429 1.3441 
HAS-8 1.3704 1.3333 1.3149 
HAS-9 1.5294 1.2324 1.2104 
HAS-10 1.4783 1.2618 1.2801 
 
 
 
Table 2.4: Calculated molar refraction and refractive index of Schiff bases 
in DMF and THF at 308.15 K.   
 
  
Compounds Solvents 
 DMF THF 
 (MRD)2 n (MRD)2 n 
HAS-1 83.25 1.6810 124 1.9637 
HAS-2 119.0 1.9875 140 2.1692 
HAS-3 151.0 2.1265 253 2.5809 
HAS-4 102.1 1.6360 187 2.6785 
HAS-5 111.0 1.8597    119.5 1.9912 
HAS-6 90.00 1.6209 166 3.9667 
HAS-7 44.00 1.2981    80.5 1.4316 
HAS-8 110.4 1.8318 120 1.8997 
HAS-9 89.40 1.7796    140.5 2.0973 
 HAS-10 112.2 2.1100    129.5 2.0843 
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Figure 2.1:  The variation of 1/g1r12 with g2/g1 for HAS-1 in [A] DMF and 
[B] THF at 308.15 K. 
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Figure 2.2 The plots of molar refraction (MRD)12 against concentration 
of Schiff bases in DMF solutions at 308.15 K. 
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Figure 2.3 The plots of molar refraction (MRD)12 against concentration 
of schiff bases in THF solutions at 308.15 K. 
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Table 2.5:     Volume increments of some atoms and groups of atoms 
 
Atom or 
Atomic  group 
Volume 
Increment (Ao)3 
Atom or  
Atomic group 
Volume 
Increment (Ao)3 
H C
1.08
 
 
1.68 
 
C S
1.81
 
4.6 
O C H
H
H
1.5
1.08
1
.0
8
 
 
 
26.3 
 
S C
1.81
 
3.92 
OCal Car
1.5 1.37
 
 
 
2.67 
S H
1.354
 
4.8 
C
C
O1.4
1.5
C
 
 
10.2 
Car
H
N C
1.28
1.
08
1.48
 
3.61 
C
C
H
1.081.4 C
 
 
14.7 
N
N S
C
1.28
1.
48
 
13.46 
CC
N
N1.37
1.2
8
1.48
 
 
8.90 
 
HO
1.08
 
4.7 
NC C
1.28 1.37
 
 
5.62 C F
1.34
 
9.2 
C
1.28
N C
1.37
 
 
7.32 Cl C
1.77
 
19.35 
N N
C
1
.2
8
0.887
 
 
5.04 
 
N
C
Car
C
1.37
1.37
 
0.9 
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INTRODUCTION
Electrical conduction is a property of ionic solutions. From a macroscopic point
of view, ionic conduction of solutions is similar to electron or hole conduction through
solid objects. In the latter cases electrones are moving without ion cores, while in the
former, charges are moving as ions. Although water itself is a very poor conductor of
electricity, the presence of ionic species in solution increases the conductance
considerably. The conductance of such electrolytic solutions depends on the
concentration of the ions and also on the nature of the ions present (through their charges
and mobilities). This property is useful for physico-chemical analysis. By conductometry,
one can determine the dissociation constants, solubilities and rate of reactions.
This method is also useful to check the purity of water, amount of nitrogen in
biological materials etc(1). An indirect conductometric screening method has been
reported for the detection of antibiotic residues in bovine kidneys(2). Sawai et al. [3]
have used this technique to investigate the growth of fungi.
Literature survey shows that conductance of many inorganic and organic
compounds have been measured in aqueous  (4-16) and non-aqueous solvents(17-20).
However, scanty data is available for Schiff bases(21-30).
Recently, conductances of some Schiff bases in DMF and DMSO have been
measured at different temperatures by Grzeszcuk and Bator(31). Further, in our laboratory,
some conductance measurements have been done for Schiff bases (32,33).
In the present work, conductance of Schiff bases are measured in
dimethylformamide (DMF) and dimethylsulfoxide (DMSO) solutions at a definite
temperature, 308.15 K over a wide range of concentration. The selection of these two
solvents (DMF and DMSO) is due to their dipolar aprotic characteristics, which avoid
any proton interference with the conductivity of complex systems(34). The solubility
restriction in solvents of different dielectric constants does not allow to study
conductance over a wide range of varying dielectric constants. Thus, the measurements
could not be done in tetrahydrofuran (THF) and 1,4-dioxan due to poor conductance in
these solvents.
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EXPERIMENTAL
All the solvents used were distilled prior to use. The solutions of different
concentrations were prepared for each Schiff base in DMF and DMSO and the
conductance of each solution was measured by using Systronics Conductivity Meter
(Model No. 306) having cell constant 0.85 cm-1 at 308.15 K. The measured conductance
was corrected by subtracting the conductance of pure solvent.
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RESULTS AND DISCUSSION
The measured conductance of each solution after correction was used to
determine the specific conductance K, which is then used for the calculation of
equivalent conductance lC. The equations used for calculating specific conductance
(K) and equivalent conductance (lC) are:
K =k.q  .......(3.1)
lC =1000K/c  .......(3.2)
where k is the measured conductance, q is the cell constant and c is the concentration
(g.equi/lit) of the solution.
The equivalent conductance of all Schiff bases in DMF and DMSO at 308.15
K, are reported in Tables 3.1 and 3.2 along with measured conductance (C). In DMSO,
the relatively low conductivities are due to greater electro relaxation effect owing to the
higher permittivity of DMSO, which contributes interionic repulsions to a larger extent
(35). It is observed that for all the systems studied, conductance increases with
concentration. The equivalent conductance (lc) is plotted against Öc for all Schiff bases
and is shown in Figures 3.1 and 3.2 at 308.15 K. It is obvious from Figures that all
Schiff bases behave as weak electrolytes. For HAS Schiff bases, the equivalent
conductance increases in DMF and DMSO uninterruptedly with decreasing
concentration.
Figures 3.1 and 3.2 shows the following order of lC in both DMF and DMSO
solvents:
In DMF   :  HAS-1> HAS-2> HAS-3> HAS-5> HAS-10-
       >HAS-4> HAS-6> HAS-9 >HAS-8> HAS-7
In DMSO:  HAS-9> HAS-7> HAS-6> HAS-3>HAS-10-
       > HAS-5> HAS-4> HAS-2>HAS-8> HAS-1
For weak electrolytes, the equivalent conductance at infinite dilution (l0) can
not be calculated by extrapolation of lC verses Öc plots. However, we have tried to
determine l0 values, by extrapolation of the plot of  lC verses Öc. These l0 values are
given in Table 3.3. For weak electrolytes, an alternative procedure can be used to
calculate l0 values.
In this procedure, l0 is related to conductivity by using the equation:
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 k = k0 + l0 c+ c f(c) ......(3.3)
where k and k 0 are the electrolytic conductivities of the solutions and solvent
respectively. c is the equivalent concentration and the function f(c) denotes the effect
of interionic interactions. The limiting conductivity (l0) can be determined accurately
from the slope, dkk/dc of the plot of kk verses c, provided other derivatives (dkk0/dc
and d[cf(c)]/dc) in the differential form of equation (3.3) are neglected as compared
to l 0, which can be determined from differential form of equation (3.3) is:
dk/dc = dk0/dc + l0 +d/dc [cf(c)] ......(3.4)
However, from the Table 3.3, it is observed that the calculated values are much
different than those observed from graphs. This suggests that equation (3.4) can not
be used for studied compounds. Further, it is mentioned in chapter 1 and 3 that
molecular interactions play an important role in solution properties. So, the derivatives
d[cf(c)]/dc which are neglected, should actually be considered.
Thus, for the studied compounds, the above used method is not
applicable at all.
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Figure 3.1:  The variation of conductance (C) with concentration for
                      Schiff bases in [A] DMF and [B] DMSO at 308.15 K.
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Figure 3.2:  The variation of conductance (C) with concentration for
                      Schiff bases in [A] DMF and [B] DMSO at 308.15 K.
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Figure 3.3:  The variation of equivalent conductance (lC) with ÖC for
                         Schiff bases in [A] DMF and [B] DMSO at 308.15 K.
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Table 3.3. The limiting equivalent conductance (l0) of all the Schiff 
bases in DMF and DMSO at 308.15 K. 
 
Compound 
code 
l0 
cm2/W.equiv. 
calc. by eq. 
(5.3) 
l0 
cm2/Wequiv. 
l0 
cm2/W.equiv. 
calc. by eq. 
(5.3) 
l0 
cm2/Wequiv. 
 DMF DMSO 
HAS-1 
HAS-2 
HAS-3 
HAS-4 
HAS-1 
HAS-2 
HAS-3 
HAS-4 
HAS-9 
HAS-10 
0.2792 
0.1800 
0.2507 
0.4326 
0.3510 
0.3197 
0.3880 
0.2096 
0.4288 
0.2899 
3.9 
5.0 
5.5 
6.2 
7.0 
6.6 
4.0 
4.6 
6.2 
5.8 
0.0584 
0.1434 
0.1599 
0.1799 
0.1545 
0.2105 
0.2023 
0.0968 
0.1933 
0.1455 
3.5 
5.0 
5.5 
7.0 
6.0 
6.3 
3.4 
3.9 
5.5 
6.1 
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INTRODUCTION
Today, an impressive array of powerful, elegant ant automated tools is available
with physical and material scientists for obtaining qualitative and quantitative information
about the composition, structure and characteristics of materials. Among the several
instruments and techniques, thermal analysis and calorimetry has grown rapidly in
recent years. This increasing importance is due to the advancement of thermal analysis
technology, relative cheapness of the equipment and time required to achieve the
desired results. In general, it is assumed that X-ray analysis is the most important tool
for evaluation of minerals, rocks; soils, clays etc., but at the same time, thermal analysis
also provide very valuable and useful information.
Thermal analysis includes a group of techniques in which specific physical
properties of a material are measured as a function of time or temperature.
Requirement for a more precise characterization of substances have increased the
demand for thermal analysis techniques. Thermal analysis have used to determine the
physical and chemical properties of polymers, electronic circuit boards, geological
materials and coals (1-3). The well facilated instrument can measure transition
temperatures, weight losses, energies of transition, dimensional changes, modulus
changes and viscoelectric properties. Both quantitative and qualitative analysis can
be carried out and one can identify and characterize the samples by qualitative
investigations of their thermal behaviors. Current areas of applications include
environmental measurements, composition analysis, product reliability, stability,
chemical reactions and dynamic properties. Further, various reversible and non-
reversible reactions(4,5), the decomposition of a compound at defined conditions, the
decomposition of molecules adsorbed on a surface, phase transitions etc. can also
be studied.
Literature survey shows that several investigations have been carried out on
the application of thermal methods in pharmaceutical industry(6-15). Wendlandt and
Collins(16) used DTA and TG techniques for the characterization and identification of
commercial non prescription analgesics. Vaddin et al(17) have studied thermal transition
of muscle protein present in fish and shell fish meat by using DSC. Starterant(18) have
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reported the biological application of DSC. A number of investigators have studied
the physical and chemical properties of various inorganic, organic and polymeric
materials(19-36) by using thermal methods. Kinetic study of thermal decomposition of
various metal complexes have also been reported by several workers(37-46).
For the study of these thermal behaviour of materials, various techniques such
as : Differential Scanning Calorimetry (DSC), Differential Thermal Analysis (DTA),
Thermo gravimetric Analysis (TGA), Evolved Gas Detection (EGD), Evolved Gas
Analysis (EGA) etc. have been used.
Differential Scanning Calorimetry (DSC):
Differential Scanning Calorimetry (DSC) has become the most widely
used thermal analysis technique. The difference in temperature between the samples
and a thermally inert reference material is measured as a function of temperature.
Reaction kinetic, purity analysis and polymer cures are the typical applications of DSC.
Further, DSC provides useful information about crystallinity, stability of crystallites, glass
transition temperature, kinetics parameters etc.
Differential Thermal Analysis (DTA):
Differential Thermal Analysis (DTA) is one of the simplest and oldest
thermal techniques employed to study the physical and chemical transformations in
the materials, associated with the energy changes. The technique involves the
measurement of temperature difference between the sample and thermally inert
reference material when both are heated simultaneously at the predetermined constant
heating rate in controlled atmosphere. Phase diagrams and thermal stability are the
prime applications of DTA.
Thermo gravimetric Analysis (TGA):
In this technique, the mass change in a sample is recorded continuously
as a function of temperature or time when it is subjected to a programmed temperature
change in a specified atmosphere. A derivative of therogravimetric curve is useful in
resolving the partially overlapping steps in the multisteps reactions involving the formation
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of weakly stable intermediates. By TGA, thermal stability and compositional analysis
can also be measured.
In this chapter, thermal properties of triazole Schiff bases have been studied
using TGA, DTA and DSC techniques.
From TGA curves, various kinetic parameters can be evaluated by several
methods. In all these methods, it is assumed that thermal and diffusion barriers are
negligible because small quantity of material is used. The shape of any TGA curve
depends on the nature of apparatus and the way in which it is used. Further, Arrhenius
equation is valid in all these methods.
  The kinetic treatments are generally based on the relationship of the type:
dC/dt = K f (C) ......(4.1)
where C is the degree of conversion, t is time and K is rate constant. f(C) is a
temperature independent function of C.
The constant K is assumed to have the Arrhenius form:
K = A e -E/RT ......(4.2)
C  can also be defined as:
C = 1-(W/W0) ......(4.3)
where W0 and W are the initial weight at t=0 and weight at any time t of the
material.
Equation (7.3) can be written as:
(W/W0) = (1-C) ......(4.4)
W/ W0 is known as residual weight fraction.
Thus, the rate of conversion is,
dC/dt = - (1/W0) (dW/dt) ......(4.5)
For homogeneous kinetics, the conversion is assumed to be of the form:
f (C) = (1-C)n ......(4.6)
where n is the order of the reaction.
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Substituting the values from equation (4.2) and (4.6) in equation (4.1) gives:
 dC/ dt = A e -E/RT (1-C)n
or   dC/dt = (A/b) e -E/RT (1-C)n ......(4.7)
where A is the frequency factor, b is the rate of heating and E is the energy of
activation.
Various methods for single and multiple heating rates have been reported(13-17).
The methods of single heating rate are as follows:
1.   Freeman-Carroll (47) and Anderson-Freeman Method (48):
At a single heating rate, Freeman and Carroll gave the following relation to
analysis TGA data :
ln (dC/dt)/ln (1-C) = n-E/R [(1/T/(Dln(1-C)] ......(4.8)
A plot of left hand side against (1/T)/(Dln(1-C)) gives a straight line with a slope
equal to -E/R and the intercept is equal to n.
Anderson and Freeman then derived the following equation by using
equation (4.8):
(Dln[dC/dt]) = n (Dln(1-C)) - E/R D(1/T)              ......(4.9)
The plot of (Dln[dC/dt]) against (Dln(1-C)) for equal intervals of D(1/T) gives a
straight line with slope equal to n and intercept -E/RD(1/T).
2. Sharp-Wentworth method (49):
To analyse the TGA data for first order kinetics (n=1), Sharp and Wentworth
gave the relation:
log [(dC/dt)/(1-C)] = log (A/b) – (E /2.303R).(1/T) ......(4.10)
The plot of log [(dC/dt)/(1-C)] against 1/T would be a straight line with slope
equal to - (E/2.303R) and intercept equal to log (A/b).
3.  Chatterjee Method(50):
Based on the weight units, the following relation was developed by Chatterjee:
n = [log(dW/dt)1-log(dW/dt)2] / (log W1-log W2)       ......(4.11)
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where W1 and W2 are the sample weights.
4.  Horowitz and Metzger method(51)  :
In this method, the value of energy of activation E can be determined from a
single TG curve by the relation:
ln [ln(1-C)-1] = (E/RTs 2)q ......(4.12)
where q = T-Ts. Ts is the temperature at which the rate of decomposition is
maximum.The frequency factor A and entropy change DS can be determined by the
following equations:
ln E - ln (RTs
2) = ln A - lnb  - E/RTs ......(4.13)
          A = (kbT / h) e 
DS/R ......(4.14)
where kb is Boltzmann constant and h is Planck’s constant.
EXPERIMENTAL
          The Differential Scanning Calorimetry (DSC), Differential thermal analysis (DTA)
and Thermo gravimetric analysis (TGA) measurements were made on the instrument
“Universal V2.6D TA Instruments at the heating rate of 10°C / min in nitrogen atmosphere
for all the triazole Schiff bases.
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RESULTS AND DISCUSSION
           The TG / DTA and DSC thermograms of Schiff bases are given in Figures 4.1
and 4.10. Various thermal properties such as initial decomposition temperature (IDT),
the decomposition temperature range and the maximum degradation along with the
percentage weight loss and Exo / Endo transitions of Schiff bases are reported in
Table 4.1.
          It is observed from the Table 4.1 that the stability of Schiff bases decrease in
order: HAS-8> HAS-1> HAS-7> HAS-10> HAS-3>HAS-4> HAS-9> HAS-5>HAS-2>HAS-6.
So, HAS-8 is most stable whereas HAS-6 is least stable. All the studied bases have
the same central moiety triazole with different side chains. Thus, the presence of
different substituent affects thermal stability. It is observed that o-chloro benzaldehyde
as side chain (in HAS-8) causes greater stability than N,N-dimethyl benzaldehyde as
in HAS-6, which is least stable. In the present case, thermal stability can not be decided
by weight loss because for all compounds, degradation is multi step process (Figures
4.1 to 4.10). Each step is of different order. The degradation in complete for HAS-3
whereas HAS-10 is least degradated. Further, the variation in the trend of thermal
decomposition might be interpreted to be of account of some intermolecular interactions
(structural as well as electronic) and also because of several experimental factors.
The melting temperature of all the triazole Schiff bases observed by DSC and
DTA are also compared with those determined by open capillary method. Although
there is good agreement between the values calculated by different methods, it was
difficult to decide the stability by these values.
The kinetic parameters, such as order of the degradation (n), energy of activation
(E), frequency factor (A) and entropy change (DS) for each step are reported in Tables
4.2 to 4.4. The Anderson-Freeman plots for HAS-1 for first and third steps are given in
Figure 4.11.
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It is evident from Tables 4.2 to 4.4 that order of reaction is quite different in
different steps for different Schiff bases. For first step, order of reaction varies from
0.2 to 4.33. For second step also, values of n varies from 1.55 to 4.90. However, for
the third step, all n values are in the range 1.61 to 1.93.
In first step, energy of activation (E) is maximum for HAS-6 and minimum for
HAS-2. The frequency factor (A) also varies in the same order i.e., maximum for HAS-
6 and minimum for HAS-2. In second step, energy of activation is not very high and
maximum is observed for HAS-1 and minimum for HAS-5. The frequency factor A is
also maximum for HAS-1 and minimum for HAS-5. In the third step, for HAS-9, both E
and A are maximum and HAS-10, these values are minimum. Comparison of E and A
values in Tables 4.2 to 4.4 shows that values of E and A are minimum for second steps
of all the Schiff bases.
Further, change in entropy (DS0) for all these reactions were also calculated by
equation (4.14). It is observed that for first and third steps, change in entropy are either
positive or negative for different Schiff bases but in second step, for all Schiff bases,
DS0 values are negative. The positive DS0 indicates that the transition state is in less
ordered state. Whereas the negative values for entropy of activation indicate that the
activation complex has a more ordered or more rigid structure than the reactants and
the reaction is slower than the normal(52).
Thus, the degradation in triazole Schiff bases is multi step process with different
order of reaction.  Further, thermal stability depends upon the type of substituent present.
It is observed that presence of o-chloro (as in HAS-8) increases the stability whereas
N,N dimethyl group (as in HAS-6) decreases the stability.
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Table 4.2: The kinetic parameters for all the compounds for 1st step.
Comp. code. n E, KJ A sec-1 DS°, JK-1 g 
HAS-1 0.21 249.79 7.20 x 1020 148.38 0.9662 
HAS-2 4.33 75.68 3.2 x 105 -145.52 0.8841 
HAS-3 1.63 202.98 6.01 x 1016 70.30 0.9098 
HAS-4 1.80 218.37 1.32 x 1018 96.01 0.9721 
HAS-5 4.29 83.86 1.76 x 106 -131.34 0.9425 
HAS-6 1.62 271.87 5.95 x 1022 185.08 0.9725 
HAS-7 2.49 112.55 6.59 x 108 -82.08 0.9872 
HAS-8 2.19 156.90 5.51 x 1012 -6.99 0.9698 
HAS-9 1.56 164.87 2.78 x 1013 6.43 0.951 
HAS-10 1.42 178.60 4.43 x1014 29.48 0.9445 
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Table 4.3: The kinetic parameters for all the compounds for 2nd step.
Comp. code. n E, KJ A sec-1 DS°, JK-1 g 
HAS-1 1.55 46.81 36.59 -223.43 0.9855 
HAS-2 3.07 14.12 0.09 -273.12 0.9313 
HAS-3 3.35 16.70 0.16 -268.57 0.9899 
HAS-4 3.88 11.37 0.05 -278.25 0.9977 
HAS-5 3.23 10.86 0.04 -279.24 0.9976 
HAS-6 4.08 12.43 0.06 -276.21 0.9913 
HAS-7 3.85 15.04 0.11 -271.45 0.9892 
HAS-8 3.01 12.92 0.07 -275.29 0.9846 
HAS-9 4.90 16.85 0.17 -268.32 0.9899 
HAS-10 2.10 21.38 0.40 -260.82 0.9869 
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Table 4.4: The kinetic parameters for all the compounds for 3rd step
Comp. code. n E, KJ A, sec-1 DS°, JK-1 g 
HAS-1 1.66 103.55 6.69 x 10
3 -182.22 0.9615 
HAS-2 1.61 107.11 1.02 x 104 -178.68 0.9750 
HAS-3 1.63 103.96 3.23 x 104 -168.24 0.9384 
HAS-4 1.93 79.35 3.28 x 102 -207.30 0.9677 
HAS-5 1.71 80.85 3.97 x 102 -205.70 0.9589 
HAS-6 1.72 98.26 3.47 x 103 -187.68 0.9843 
HAS-7 1.72 98.57 8.20 x 103 -180.02 0.9551 
HAS-8 1.62 95.80 2.58 x 103 -190.14 0.9470 
HAS-9 1.78 120.74 5.48 x 104 -164.74 0.9889 
HAS-10 1.69 35.67 4.30 -241.51 0.9959 
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Figure 1.1: The TGA/DTA and  DSC graphs  of HAS-1.
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Figure 1.2: The TGA/DTA and  DSC graphs  of HAS-2.
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Figure 1.3: The TGA/DTA and  DSC graphs  of HAS-3.
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Figure 1.4: The TGA/DTA and  DSC graphs  of HAS-4.
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Figure 1.5: The TGA/DTA and  DSC graphs  of HAS-5.
245
Figure 1.6: The TGA/DTA and  DSC graphs  of HAS-6.
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Figure 1.7: The TGA/DTA and  DSC graphs  of HAS-7.
247
Figure 1. 8: The TGA/DTA and  DSC graphs  of HAS-8.
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Figure  1.9: The TGA/DTA and  DSC graphs  of HAS-9.
249
Figure 1.10: The TGA/DTA and  DSC graphs  of HAS-10.
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Figure 4.11:   The Anderson-Freeman plots for HAS-1 for second [A] and third
  [B] step.
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INTRODUCTION
The energy change associated with the process in which a solute dissolves in
a solvent is called the heat of solution. It is equal to difference between the energy that
must be supplied to break up the crystal of the solute and the energy that released
when the solute particles are taken into solution by the solvent. When the temperature
will decrease, the heat of solution is negative where as increase of the temperature
gives positive heat of solution. The heat of solution is defined as the change in enthalpy
when one mole of substance is dissolved in specified quantity of solvent at a given
temperature.
The molar heat of solution and melting temperature of a substance can be
determined from the solubility measurements at different temperatures(1). The heat of
solution for many inorganic and organic compounds has been reported (2-13). Meurs et
al. studied the heat of solution of some polymers(14).
The thermodynamic properties of several electrolytes in different solvents have
been studied by many workers(15-21). In our laboratory, heat of solution of some Schiff
bases has also been determined(22, 23).
In the present work, heat of solution for some triazole Schiff bases was
determined in 1, 4-dioxane (DO) and tetrahydrofuran (THF) at different temperatures
(308.15 to 328.15 K).
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EXPERIMENTAL
           The solvents used for the measurements were purified and fractionally distilled
prior to use by the method reported in the literature(24). The solubility of each Schiff
base was determined by transferring 25 ml of saturated solution into a pre-weighed
50 ml beaker at a definite temperature. The weight of beaker along with solution was
taken and the solvent was evaporated to dryness until constant weight is obtained.
This gives the weight of solute present in 25 ml saturated solution. Three replicate
measurements were carried out at a particular temperature and average value of weight
was determined. The experiment was repeated at other temperatures also. Subtraction
of weight of solute from the weight of solution gives the weight of solvent in 25 ml
saturated solution.
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RESULTS AND DISCUSSION
The solubility (N2) of Schiff bases in 1, 4-dioxane and THF are given in Tables
5.1 and 5.2. It is evident from Tables 5.1 and 5.2 that the solubility of Schiff bases
increases with temperature in both the solvents. Comparison of solubility of these bases
in THF and 1,4-Dioxan   (Table 5.1 and Table 5.2) shows that overall solubility is greater
in THF than in 1, 4-dioxane. Further, in THF, solubility varies much for different bases
whereas in 1,4-dioxan, except for HAS-5, HAS-8 and HAS-10, solubility does not differ
much for different bases.   Thus, the solvent polarity plays an important role on the
solubility of Schiff bases studied.
 The variation of solubility with temperature is given by:
[( ln N2) / ¶T]P = DHS / RT
2 ………. (5.1)
where N2 is the solubility or mole fraction, T is absolute temperature of the experiment,
DHS is the heat of solution and R is gas constant.  Integration of equation (1) between
temperature limits from T and Tm gives:
ln N2 = [DHS (T- Tm)] / RT.Tm ……….(5.2)
where T and Tm are the temperature of the experiment and melting temperature of the
Schiff bases.
Figure 5.1 shows the variation of ln N2 with 1/T for a Schiff base (HAS-1) in [A]
1, 4-dioxane and [B] THF solutions.
From the plots, melting temperatures of Schiff bases were also calculated and
are given in Table 5.3 along with experimental values determined by open capillary
method. The melting points measured by DSC and DTA are also given in Table 5.3.
Comparison of melting points calculated by different methods shows that in most of
the cases, good agreement is observed between values calculated from solubility
data and those observed by open capillary method and DSC/DTA. However, in some
cases, discrepancies are observed, mostly in 1, 4-dioxan. For some Schiff bases,
values could not be calculated due to non linear behavior of ln N2 against 1/T.
        Further, heat of solution are observed to be positive for all the Schiff bases (Tables
5.1 and 5.2) indicating thereby endothermic behavior of these bases in both the
solvents.
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Table 5.1: The solubility and heat of solution of Schiff bases in 
Tetrahydrofuran at different temperatures. 
 
Temp. 
K 
N2 
(.103) 
DHs 
(K.cals/mol) 
N2 
(.103) 
DHs 
(K.cals/mol) 
 HAS-1  HAS -6 
308.15 15.0132 15.4232 14.7112 14.7212 
318.15 15.1750 16.7558 15.1129 15.8608 
328.15 15.4186 18.2177 15.3308 17.1660 
 HAS -2 HAS -7  
308.15 16.8100 15.6242 11.0275 16.3997 
318.15 17.3752 16.9421 18.4173 15.8162 
328.15 17.6245 18.5015 18.6035 17.2021 
 HAS -3 HAS -8 
308.15 23.5394 13.9981 9.1260 16.6758 
318.15 17.4398 16.4903 9.4071 17.9921 
328.15 18.0097 17.8840 9.6294 19.4737 
 HAS -4 HAS -9 
308.15 15.5839 15.0471 3.4335 21.1142 
318.15 16.7792 16.0756 4.1969 22.2110 
328.15 17.0229 17.8840 15.1297 18.5862 
 HAS -5 HAS -10 
308.15 11.3804 17.6187 5.0356 18.6220 
318.15 11.7120 19.1894 5.4459 19.9081 
328.15 12.5051 20.7839 5.7471 21.4144 
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Table 5.2:  The solubility and heat of solution of Schiff bases in 1, 4-
dioxan at different temperatures. 
 
 
Temp. 
0C 
N2 
(.103) 
DHs 
(K.cal/mol) 
N2 
(.103) 
DHs 
(K.cal/mol) 
 HAS-1  HAS -6 
308.15 17.7516 14.8078 17.4026 14.1350 
318.15 18.0386 16.0642 17.8503 15.2309 
328.15 18.3166 17.4656 18.1137 16.4807 
 HAS -2 HAS -7  
308.15 19.9444 14.9706 21.4721 13.9751 
318.15 20.2078 16.3108 21.7384 15.1598 
328.15 20.2087 17.8747 21.8636 16.5050 
 HAS -3 HAS -8 
308.15 20.4129 14.5302 10.6248 16.1359 
318.15 20.9260 15.7481 10.8944 17.4261 
328.15 20.9806 17.2042 11.1039 18.8761 
 HAS -4 HAS -9 
308.15 18.4732 14.4322 17.2309 15.1127 
318.15 18.5031 15.6910 20.3242 15.8097 
328.15 19.0221 16.9800 20.5864 17.2204 
 HAS -5 HAS -10 
308.15 13.3443 16.9923 5.5871 18.2563 
318.15 13.6190 18.5384 5.8653 19.6248 
328.15 13.9046 20.2807 6.1639 21.1238 
 
258
Table 5.3:  Melting points of Schiff bases calculated from different methods.
Code. Open 
capillary 
Method  
0 C 
DSC/DTA 
0 C 
THF 
[cal. by eqn.2]  
0 C 
DO 
[cal. by eqn.2] 
0 C 
HAS-1 227 241/239 195.94 209.08 
HAS-2 215 217/218 269.25 101.87 
HAS-3 222 218/219 - 182.87 
HAS-4 232 220/224 262.91 196.04 
HAS-5 207 222/221 313.32 272.58 
HAS-6 242 267/226 264.22 245.05 
HAS-7 230 229/244 402.00 129.95 
HAS-8 238 228/242 353.70 305.11 
HAS-9 223 236/252 - - 
HAS-10 241 217/226 323.15 450.20 
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Figure 5.1: The variation of lnN2 against 1/T for HAS-1 Schiff bases in [A] 
THF and [B] 1,4-Dioxan. 
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INTRODUCTION
Biological Activity Spectrum of a compound represents the pharmacological
effects, physiological and biochemical mechanisms of action, specific toxicity which
can be revealed in compounds interaction with biological system. Further, it describes
the intrinsic properties of the compound which depends on its structure. Most of known
biologically active substances have many biological activities such as antibacterial,
anti-inflammatory, antifungal, anti-HIV, antipyretic, antitumor etc.
A literature survey shows that a number of triazole derivatives have been tested
for antimicrobial activities. Many of them have been found to exhibit bacteriostatic and
fungistatic activities(1-5). Further, the Schiff bases have been reported to demonstrate a
wide range of pharmacological (6-10) activities, which include antibacterial(11-13),
antifungal(14), anti-HIV (15), antitumor(16), anti-inflammatory(17), antipyretic(18-19) etc. They are
found to be active against a wide range of both Gram positive and Gram negative
bacteria(20-21). Many Schiff bases have been known to be medicinally important and
are used to design medicinal compounds(22-26). Schiff bases of some triazoles have
also been reported to have biological activities(27-30). Considering these properties of
triazole derivatives, in the present chapter, biological activities of some of these
compounds were studied using strains of Gram positive and Gram negative bacteria.
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EXPERIMENTAL
ANTIBACTERIAL ACTIVITY
The antibacterial activities of the triazole Schiff bases and 4-aryl triazoles were
studied in dimethyl formamide (DMF), dimethylsulfoxide (DMSO) and 1,4-dioxan (DO).
All these solvents were purified before use by standard methods. The synthesized
compounds were also recrystallized. For comparison, the antibacterial activities of
intermediates were also studied.
Preparation of test compounds
For Schiff bases, the solutions were prepared in 1,4-dioxan and DMF. These
bases were dissolved at a concentration of 15 mg / ml in either of the two solvents
(DO/DMF) in order to make the final concentration 1.5 mg / 0.1 ml.
For 4-aryl triazoles, the solutions were prepared in DMSO only. For these
compounds, due to poor solubility, 1,4-dioxan or DMF could not be used. The 4-aryl
triazole derivatives were dissolved at a concentration of 10 mg / ml in DMSO.
Test microorganisms
The bacterial strains studied are identified strains and were obtained from
National Chemical Laboratory (NCL), Pune, India. The investigated micro organisms
are P. pseudoalcaligenes ATCC 17440, P. vulgaris NCTC 8313, C. freundii ATCC
10787, E. aerogenes ATCC 13048, S. subfava NCIM 2178 and B. megaterium ATCC
9885.
Preparation of plates and microbiological assay
A loop full of the given test strain was inoculated in 25 ml of N-broth (Nutrient
Broth) and was incubated for 24h in an incubator at 37o C in order to activate bacterial
strain 28-30 ml of the Mueller Hinton Agar No.2 media was added into the 100 mm
diameter Petri-plate. Inoculation was done by the Pour-plate technique. 0.2 ml of the
activated strain was inoculated into the media when it reached 40-45o C. The complete
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procedure of the plate preparation was done in the laminar airflow to maintain strict
sterile and aseptic condition. The media was allowed to solidify. After solidification of
the media, ditch / well(31) was made in the plates with the help of cup-borer (0.85 cm)
and then it was filled with the solution of synthesized compounds. The controls were
maintained (for each bacterial strain and each solvent), where pure solvent was
inoculated into the well. The plates were incubated for 24 h at 37oC.  The inhibition
zone formed by these compounds against the particular test bacterial strain determined
the antibacterial activity of the synthetic compounds. The mean value obtained for
three individual replicates was used to calculate the zone of growth inhibition of each
sample.
ANTIFUNGAL ACTIVITY
A total of 25 compounds were screened for In vitro antifungal activity against
Candida tropicalis (ATCC 4563), Candida albicans (ATCC 2091), Cryptococcus
neoformans (ATCC 34664), Trichosporon beigelii (NCIM 3404) and Aspergillus
flavus (NCIM 538) spores by disc diffusion assay at the concentrations 500 µg/disc.
Fluconazole was used as standard drug. The test solutions were prepared in DMSO.
Blank experiment with DMSO alone was done which also works as control.
From the antifungal screening, it was found that the compounds screened
showed significant activity, some are equipotent to the standard drug whereas others
are found to be more potent than the standard drug.
Antifungal assay
To evaluate the antifungal activity, sterile agar plates were used according to
the disc diffusion assay. Activated cultures of fungal strains (Candida tropicalis ATCC,
Candida albicans ATCC2091, Cryptococcus neoformans ATCC34664, Trichosporon
beigelli NCIM3404, and Aspergillus flavus NCIM538) in Sabouraud’s broth were
adjusted to 1x 108 cfu/m as per Mcfarland standard. 100 ml of the inoculum was
introduced to molten sabouraud dextrose agar and poured in the sterile petri plates.
Sterile filter paper discs (7.0 mm diameter) were impregnated with 500 mg/disc of the
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test compounds dissolved in 100% DMSO (dimethylsulphoxide) and dried. The discs
were placed on fungal-seeded plates and incubated at 28°C for 48 hours. Discs
impregnated with only 100% DMSO served as the negative control. As a positive
control, fluconazole and ketoconazole were used. Following an incubation period of
48 hrs., plates were removed from the incubator and antifungal activity was evaluated
by measuring zones of inhibition of fungal growth. Clear zones within which fungal
growth was absent were measured and recorded as the diameter (mm) of complete
growth-inhibition. The whole experiment was performed three times to minimize the
error.
265
RESULTS AND CONCLUSION
ANTIBACTERIAL ACTIVITY
SCHIFF BASES
The antibacterial activity of triazole derivatives showed a differential activity
against the bacterial strains investigated.  The activity was also observed to be solvent
dependent.  The antibacterial activity of all the intermediates and Schiff bases in both
the solvents DO and DMF against E. coli and P. aeruginosa is shown in Fig.1.   None
of the compounds in either of the solvent could inhibit P. aeruginosa except an
intermediate HAS-B i.e., ester.  On the other hand, considerable activity was envisaged
against E.coli in both the solvents. The compounds in 1,4-dioxan showed better
antibacterial activity than in DMF. It is observed that compounds HAS-A, HAS-B, HAS-
C, HAS-D and HAS-E showed best antibacterial activity against this Gram negative
bacteria i.e. E.coli.  In fact, the best activity was shown by the very starting compound
HAS-A i.e. 4-methoxy benzoic acid and HAS-D its salt, dithiocarbazate. However,
both these compounds HAS-A and HAS-D did not show much antibacterial activity in
DMF.  The compound HAS-E i.e., 1,2,4 triazole showed comparatively less activity in
both the solvents.  However, In 1,4-dioxan, HAS-2, HAS-3 and HAS-5 showed some
activity and in DMF HAS-2 and HAS-3 showed activity. But, these activities are less
than the starting compounds and some intermediates. HAS-2 contains p-methoxy
benzaldehyde as side chain and HAS-3 contains p-fluoro benzaldehyde as side chain.
Thus, these two side chains are effective to inhibit E.coli. This differential
response of the compounds is because of the structural differences amongst them.  In
the present work, out of 15 compounds studied, HAS-A is starting compound and
HAS-B to HAS-E are intermediates. Rest HAS-1 to HAS-10 are synthesized Schiff
bases of triazoles in which, different side chains are attached to the compound HAS-
E i.e. 1,2,4-triazole. The structures of all the compounds are given in part-1,chapter-
1,Section-I,page (12). Thus, it is obvious that the group or the molecule that is attached
to the central ligand play an important role in inhibiting the bacteria.  The inhibition of
bacterial growth also depends on the solubility of the compounds in a particular solvent,
its diffusion capacity and penetration into the bacterial cell wall.
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The antibacterial activity against two Gram positive bacteria S. aureus and B.
cereus are shown in Fig. 2.  None of the compounds in either of the solvent could
inhibit the Gram positive bacteria S. aureus except a very negligible activity was shown
by HAS-A and HAS-D. An entire different trend was observed against B. cereus. A
considerable activity was shown by most of the compounds in both the solvents.
Maximum activity was shown by compound HAS-D followed by compound HAS-A,
though the activity was more in 1,4-dioxan. Compounds
HAS-1, HAS-4 and HAS-6 showed considerable activity against B. cereus in
both solvents while the others could not inhibit this bacterial strain. HAS-1 contains
hydroxyl benzaldehyde, HAS-4 contains Vanillin and HAS-6 has n, n-dimethyl
benzaldehyde as side chain attached to triazole moiety. Thus, these three are more
effective againsts B. cereus in both the studied solvents.
The antibacterial activity against Gram negative bacteria A. fecalis and K.
pneumoniae are shown in Fig. 3.  The antibacterial activity against A. fecalis is similar
to that of E. coli. i.e., HAS-A to HAS-E showed considerable antibacterial activity in
both the solvents. However, activity is more when the solvent used was non polar solvent
1,4-Dioxan. In DO HAS-2, HAS-3 and HAS-5 showed negligible activity while other
compounds showed no activity at all against A. fecalis. In DMF also, only HAS-4 and
HAS-5 showed negligible activity whereas others showed no activity at all.  An entirely
different trend was observed against K. pneumoniae. In DMF, all the studied
compounds showed considerable activity. However, in DO, only HAS-1, HAS-7, HAS-
8 and HAS-9 could inhibit K. pneumoniae.  The compounds HAS-A to HAS-E, which
showed antibacterial activity in 1,4-Dioxan against the other five bacterial strains, did
not inhibit this bacteria at all whereas in DMF, these intermediates showed considerable
activity. But, comparison of intermediates with synthesized Schiff bases show that
only HAS-1, HAS-7 and HAS-10 showed better activity than intermediates. HAS-1
contains p-hydroxy benzaldehyde as side chain; HAS-7 contains 3-nitro benzaldehyde
as side chain whereas HAS-10 has benzaldehyde as side chain. Thus, only hydroxyl
and nitro groups attached to benzene ring inhibit K. pneumoniae. Other groups have
less or almost no effect on this bacteria.
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From the present work, it can be concluded that inhibition depends on the
molecular structure of the compound, the solvent used and the particular bacterial strain.
Amongst the solvents used, 1,4-dioxan appears to be better than DMF.  This is
in agreement with our earlier work(30) that non-polar solvents may be beneficial in our
attempt to search lead molecules for drug designing.
B. cereus appeared to be most susceptible bacteria while P. aeruginosa was
the most resistant bacterial strain. Except K. pneumoniae, none of the newly synthesized
triazole compounds could inhibit any of the bacterial strains investigated.  Hence, though
triazole compounds are reported to show many pharmacological activities but these
studied compounds did not show much antibacterial activity.
Therefore, such screening of various organic compounds and identifying active
agents is the need of the hour; because successful prediction of lead molecule and
drug like properties at the onset of drug discovery will pay off later in drug development.
4-ARYL TRIAZOLES
The antibacterial activity of all the ten (HASD-1 to HASD-10) compounds in
DMSO against above mentioned bacteria are shown in Fig.4. It is observed that HASD-
6 shows maximum activity against Bacillus cereus followed by HASD-2. HASD-4,
HASD-7, HASD-8 and HASD-9 also showed some negligible activity whereas HASD-
1, HASD-3, HASD-5 and HASD-10 showed no activity at all. The response of
synthesized compounds against different bacteria is because of different groups
present in it. HASD-6 contains 2, 4-dimethyl group whereas HASD-2 contains p-
methoxy group.
Thus 2, 4-dimethyl and p-methoxy groups affect B.cereus in DMSO.  Against
P.testosteroni, again HASD-6 showed maximum activity followed by HASD-2, HASD-
10 and HASD-1 also showed activity. HASD-10 and HASD-1 contain o-methoxy and
p-methyl group which are found to be effective against P.testosteroni. Other compounds
had no effect at all against P.testosteroni.  Again against K.pneumoniae, HASD-6
showed maximum activity. HASD-3 and HASD-9 showed no activity at all against this
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bacteria. Other compounds showed some activity. Against M.flavus HASD-1 showed
maximum activity followed by HASD-6 and HASD-7. All other compounds had no effect
on M.flavus. HASD-1 contains p-methyl as side chain, HASD-6 contains 2,4-dimethyl
as side chain and HASD-7 has 2,3-dichloro as side chain. The antibacterial activity
against C.freundii was observed only by HASD-6 and HASD-4. Others had no effect
at all.
The substituted groups present in different compounds have different effect
against different bacteria. It is observed from above finding that 2, 4-dimethyl group
present in HASD-6 are most effective.   P-cl group and 3-chloro-4-fluoro group present
in HASD-3 and HASD-9 respectively are not effective for the bacteria taken in the
present study.
The most susceptible bacteria is K.pneumoniae and most resistant is
C.freundii.
ANTIFUNGAL ACTIVITY
SCHIFF BASES
The inhibition against different fungal strains for different synthesized compounds
along with starting material and intermediates are given in Figures 5 to 7. It is observed
from Figure 5 that for all the fungal strains, starting material HAS-A showed maximum
inhibition than intermediates. Against Cryptococcus neoformans, it showed more
inhibition than standard drug Fluconazole whereas HAS-D and HAS-E showed no
inhibition at all. The inhibition depends upon the fungal strain and on the structure of
the compounds. HAS-B showed minimum inhibition against Candida tropicalis. HAS-
B and HAS-C showed no inhibition against Candida albicans. HAS-E did not affect
Trichosporon beigelii whereas Aspergillus flavus was not affected by HAS-C.
Figures 6 and 7 show  that HAS-2 showed maximum inhibition against Candida
tropicalis whereas HAS-1, HAS-5, HAS-6, and HAS-8 could not affect this fungal strains.
All these compounds have same central moiety with different substituted groups. Thus,
different substituted groups affect differently for different fungal strains.
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However, Candida albicans was maximum affected by HAS-1 while HAS-2,
HAS-3, HAS-4, HAS-9 and HAS-10 showed no effect on this. Against Cryptococcus
neoformans HAS-3 showed maximum inhibition followed by HAS-4. HAS-2 and HAS-
9 also showed inhibition whereas other had no affect.
Further, HAS-3 showed maximum inhibition against Trichosporon beigelii and
Aspergillus flavus followed by HAS-4. For Trichosporon beigelii HAS-1, HAS-6, HAS-
7, HAS-8, HAS-9 showed no activity whereas for Aspergillus flavus HAS-1, HAS-7
and HAS-10 showed no activity at all.
This observation suggests that overall fluoro benzaldehyde substitution (HAS-
3) inhibited maximum whereas p-hydroxy benzaldehyde (HAS-1) could affect only
Candida albicans. Out of all the 5 studied fungal strains, Cryptococcus neoformans
is most resistant fungal and Candida albicans could be inhibited by most of the Schiff
bases.
Comparison of all these HAS compounds with standard Fluconazole shows
that these synthesized compounds inhibit the studied fungal strain less that that of
Fluconazole. Thus, the synthesized compounds are not promising antifungal agents.
Further, it is observed that against Candida tropicalis and Candida albicans there is
only slight change in the activity of starting material and some Schiff bases. For
Cryptococcus neoformans, Trichosporon beigelii and Aspergillus flavus, starting
material showed maximum inhibition than most of the Schiff bases.
4-ARYL TRIAZOLES
However, different trend is observed for HASD compounds (Figures 6 and 7).
It is observed that maximum inhibition was observed for HAS-D6 against all the studied
fungal strains. Against Candida tropicalis HASD-3 showed no inhibition at all whereas
against Candida albicans, HASD-1, HASD-5 and HASD-10 had no effect. HASD-8
showed maximum inhibition against Cryptococcus neoformans whereas HASD-3,
HASD-9 and HASD-10 could not affect. For Trichosporon beigelii also HASD-3 and
HAS-10 had no affect at all whereas only HASD-3 could not affect Aspergillus flavus
, other compounds showed considerable inhibition against this fungal strain.
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In all HASD compounds, central moiety in same with different substitutions.
The 2,4- dimethyl aniline substitution (in HASD-6) is most effective for all the studied
fungal strains. However, for Cryptococcus neoformans o-methyl aniline (in HASD-8)
affected most, p-chloro aniline (in HASD-3) and o-methoxy aniline (in HASD-10) affect
minimum.
When compared with Fluconazole, it is evident from Figures 4 and 5 that for
Cryptococcus neoformans, Trichosporon beigelii and Aspergillus flavus some of these
compounds are more active than Fluconazole. Highest activity was observed for HASD-
8 followed by HASD-6 and HASD-7 against Cryptococcus neoformans. Further, it is
observed that all the studied fungal strains are susceptible to the almost synthesized
HASD compounds.
Comparison of inhibition zones by HASD with HAS compounds shows that
HASD are more effective against the studied fungal strains than HAS. This again
proves that the effect of structure of compounds. Out of all the 10 each HAS and HASD
compounds, 3 of each series have common substituted groups but different central
moiety. The comparison of inhibition produced again proved that presence of -C=N-
group reduces the antifungal activity.
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    Figure 4:  Antibacterial activity of 4-aryl triazoles in DMSO
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A COMPREHENSIVE CONCLUSION OF THE WORK
The thesis is divided into three parts. First part comprised of synthesis and
characterization of compounds. In the second part, physicochemical properties of some
compounds have been studied whereas in the third part, biological activities of some
compounds are reported.
PART-1: SYNTHESIS AND CHARACTERISATION
CHAPTER-1: This chapter describes the synthesis and characterization of some
  triazole derivatives, which is further mentioned by three different
  sections.
SECTION-I: In this section, literature, synthesis and characterization of some Schiff
bases derived from 1, 2, 4-triazole are reported.
SECTION-II: Introduction of some 4-aryl triazoles is given here along with their
synthesis and spectral data.
SECTION-III:  The introduction, synthesis and spectral data of some 1,3,4-
thiadiazole derivatives are reported in this section.
CHAPTER-II:  In this chapter, synthesis of some pyazoles has been reported. Their
characterization by IR, 1H NMR and Mass spectroscopy was also done
and given in this chapter. Further, it is divided into four sections.
SECTION-I:   In this section, synthesis and characterization of some chalcones
derived from pyrazoles are reported.
SECTION-II:    This section describes the synthesis and characterization of some
pyrazolines.
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SECTION-III:    Synthesis of some cyanopyridine derivatives are reported in this
section along with their spectral data.
SECTION-VI:    In this section, synthesis of some thiazolidinone derivatives has been
reported along with their spectral data.
CHAPTER-3: In this chapter, some pyrazolines are synthesized by three different
methods: conventional, microwave and ultrasonic techniques.
Comparison of these methods shows that both microwave and
ultrasonic methods give comparatively good yield of products than
conventional method. Further, by using these techniques, reaction time
is reduced to few minutes (in microwave) and to few hours (in ultrasonic
technique). It is also observed that no catalyst is required for synthesis
of compounds by ultrasonic technique.
PART-2: PHYSICO CHEMICAL PROPERTIES
    This part is divided in five chapters.
CHAPTER-I:       To understand the interaction occurring in the solution, the acoustical
properties of Schiff bases are measured in DMF and  THF at
308.15K. It is observed that solute-solute and solute-solvent
interactions exist in all the solutions.
CHAPTER-II:    In this chapter, the density and refractive index of Schiff bases are
measured in DMF and THF at 308.15K. It is observed that, there is
deviation between experimental and calculated values of densities,
which again suggest the presence of intermolecular interactions
between solute and solvent molecules. Further, the refractive index
of Schiff bases has been evaluated from the experimental refractive
index values of the solutions in DMF and THF.
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CHAPTER-III: This chapter describes the conductance of Schiff bases in DMF
and THF at 308.15K. The equivalent conductance is found to
increases with dilution. The equivalent conductance is observed to
depend on solvent and nature of solute rather than on its molecular
weight. Further, it is observed that all the Schiff bases are weak
electrolytes.
CHAPTER-IV:     In this chapter, thermal properties of Schiff bases are studied. Thermal
stability is found to be affected by the substituent groups. HAS-1 is
observed to be more stable whereas HAS-4 is observed to be less
stable. Various kinetics parameters such as order of reaction, energy
of activation, frequency factor and entropy change were calculated.
Each Schiff base follows multisteps decomposition. Further, the value
of entropy change is observed to be positive which suggest the less
ordered transition state.
CHAPTER-V:    This chapter describes the heat of solution of Schiff bases in 1,4-
dioxane and THF at different temperatures. It is observed that
solubility of Schiff bases increases with temperature. The solubility
of Schiff bases are observed to be greater in THF than in 1, 4-
dioxane. The melting temperature of Schiff bases are also calculated
by using solubility data. In most of the cases, good agreement is
observed between calculated from solubility data and those observed
experimentally, DCS and DTA data. Further, heat of solution is
observed to be positive for all the Schiff bases in both the solvents
indicating thereby exothermic behavior of Schiff bases.
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PART-3: BIOLOGICAL ACTIVITIES
           The biological activity i.e., antibacterial and antifungal activities of some Schiff
bases  and 4-aryl triazoles are studied in this chapter. For antibacterial activity, 1,4-
dioxan and DMF are used for Schiff bases where as for 4-aryl triazoles, only DMSO is
used. It is observed that substituent attached to the central moiety and solvent polarity
play an important role in inhibiting the bacteria.  Amongst the solvents used for Schiff
bases, 1,4-dioxan is found to be better than DMF. B. cereus is found to be most
susceptible bacteria while P. aeruginosa is most resistant bacterial strain for Schiff
bases. In case of 4-aryl triazoles, most susceptible bacteria is K. pneumoniae and
most resistant is C. freundii.
For antifungal activities, DMSO is used for both types of compounds. It is
observed that in case of Schiff bases, overall HAS-3 containing fluoro benzaldehyde
inhibited maximum whereas HAS-1 containing p-hydroxy benzaldehyde, inhibited
minimum.  However, in case of 4-aryl triazoles, HASD-6 containing 2,4-dimethyl aniline
substitution is most effective for all the fungal strains.
Comparison of antifungal activity of Schiff bases and 4-aryl triazoles shows
that 4-aryl triazoles are more effective against the studied fungal strains. This again
proves that structure of compound plays an important role in activity. Thus, presence of
C=N group reduces the activity. This is further proved by comparing the activity of
these compounds with the standard Fluconazole. It is observed that most of 4-aryl
triazoles are more active than Fluconazole whereas Schiff bases are less than that of
Fluconazole.
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